

**GMO FUNDS PLC**

(an umbrella fund with segregated liability between sub-funds)

**ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS DEDICATED TO THE SWISS  
MARKET**

**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**Registered Number 351477**

Notification pursuant to Sec. 310 of the German Capital Investment Code (Kapitalanlagegesetzbuch) has been filed for GMO Quality Investment Fund and the shares in this fund may be marketed to investors in the Federal Republic of Germany.

Certain of the sub-funds of GMO Funds Plc (the “Company”) are not approved for offer in Switzerland. Accordingly, no reference is made to these sub-funds in this abridged version of the annual report and audited financial statements.

The Prospectus, the Key Investor Information Document (KIID), the most recent annual and semi-annual reports as well as the portfolio changes may be obtained free of charge from the representative and paying agent in Switzerland. The Swiss representative and the paying agent of the Company in Switzerland is State Street Bank International GmbH, Munich, Zurich Branch, Kalanderplatz 5, CH - 8027 Zurich, Switzerland.

---

**GMO FUNDS PLC**  
**ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS**  
**TABLE OF CONTENTS**

---

	<b>Page</b>
Directors' Report	1
Remuneration Policy (Unaudited)	
Remuneration Policy for the Investment Manager (Unaudited)	5
Remuneration Policy for the Manager (Unaudited)	6
Statement of Depositary Responsibilities and Depositary Report	7
Independent Auditors Report	8
Investment Manager's Report	
GMO Quality Investment Fund	10
Statement of Investments	
GMO Quality Investment Fund	11
Portfolio, Counterparty and Currency Abbreviations	15
Statement of Comprehensive Income	16
Statement of Financial Position	17
Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares	18
Notes to the Financial Statements Dedicated to the Swiss Market	19
Statement of Changes in the Portfolio (Unaudited)	
GMO Quality Investment Fund	62
Directory	63

---

**GMO FUNDS PLC**  
**DIRECTORS' REPORT**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

The Directors present to the shareholders their annual report together with the audited financial statements of GMO Funds Plc (the “Company”) for the financial year ended 30 September 2025.

**Directors’ Responsibilities Statement**

The Directors are responsible for preparing the Directors’ Report and the financial statements in accordance with Irish law. Irish law requires the Directors to prepare financial statements for each financial year giving a true and fair view of the Company’s assets, liabilities and financial position at the end of the financial year and the profit or loss of the Company for the financial year. Under that law the Directors have arranged for the preparation of the financial statements in accordance with the accounting standards issued by the Financial Reporting Council of the UK, including Financial Reporting Standard 102, the financial reporting standard applicable in the UK and the Republic of Ireland and the European Community (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended) (the “UCITS Regulations”) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the “Central Bank’s UCITS Regulations”).

Under Irish law, the Directors shall not approve the financial statements unless they are satisfied that they give a true and fair view of the Company’s assets, liabilities and financial position as at the end of the financial year and the profit or loss of the Company for the financial year.

In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards and identify the standards in question, subject to any material departures from those standards being disclosed and explained in the notes to the financial statements; and
- arrange for the preparation of the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping adequate accounting records that are sufficient to:

- correctly record and explain the transactions of the Company;
- enable, at any time, the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy; and
- enable the Directors to ensure that the financial statements comply with the Companies Act 2014 and enable those financial statements to be audited.

The Directors are responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In this regard, the Directors have entrusted the assets of the Company to State Street Custodial Services (Ireland) Limited (the “Depository”) who has been appointed as Depository of the Company.

In accordance with Section 330 of the Companies Act 2014, the Directors in office at the date of this report have each confirmed that:

- As far as he/she is aware, there is no information relevant to the preparation of the financial statements of which the Company’s auditor is unaware; and
- He/she has taken all the steps that he/she ought to have taken as a Director in order to make himself/herself aware of any information relevant to the preparation of the financial statements and to establish that the Company’s auditor is aware of that information.

In regard to the foregoing requirements, the Directors have relied on Grantham, Mayo, Van Otterloo & Co. LLC (the “Investment Manager” or “GMO LLC”), State Street Fund Services (Ireland) Limited (the “Administrator”) and Depository and the representations provided by such parties to the Directors.

---

**GMO FUNDS PLC**  
**DIRECTORS' REPORT (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**Directors' Responsibilities Statement (continued)**

The Investment Manager is responsible for the maintenance and integrity of the corporate and financial information in respect of the Company included on GMO LLC's website. Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Directors' Compliance Statement**

It is the policy of the Company to comply with its relevant obligations (as defined in the Companies Act 2014). As required by Section 225(2) of the Companies Act 2014, the Directors acknowledge that they are responsible for securing the Company's compliance with the relevant obligations. The Directors have drawn up a compliance policy statement as defined in Section 225(3)(a) of the Companies Act 2014 and a compliance policy which refers to the arrangements and structures that are in place and which are, in the Directors' opinion, designed to secure material compliance with the Company's relevant obligations. These arrangements and structures were reviewed by the Company during the financial year. In discharging their responsibilities under Section 225, the Directors relied upon, among other things, the services provided, advice and/or representations from third parties whom the Directors believe have the requisite knowledge and experience in order to secure material compliance with the Company's relevant obligations.

**Accounting Records**

The Directors are responsible for ensuring that adequate accounting records are kept in respect of the Company as outlined in Sections 281 to 286 of the Companies Act 2014, which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2014. To achieve this, the Directors have delegated the accounting function to the Administrator, to ensure that the requirements of Sections 281 to 286 of the Companies Act 2014 are complied with. The accounting records of the Company are maintained at the Administrator's office, 78 Sir John Rogerson's Quay, Dublin 2, Ireland.

**Connected Persons**

In accordance with Section 43(1) of the Central Bank UCITS Regulations, any transaction carried out with the Company by Waystone Management Company (IE) Limited (the "Manager") or the Depositary (excluding any non-group company sub-custodians appointed by the Depositary) and any associated or group company of the Manager, the Depositary, delegate or sub-delegate ("Connected Persons") during the period were required to be conducted at arm's length. Such transactions must be in the best interests of the shareholders of the Company.

It has been confirmed by the Board of Directors of Waystone Management Company (IE) Limited ("WMC") that they are satisfied that:

- (i) there are arrangements (evidenced by written procedures) in place to ensure that the obligations set out above are applied to all transactions with Connected Persons; and
- (ii) all transactions with Connected Persons entered into during the period complied with these obligations.

**Business Review**

GMO Quality Investment Fund's ("Quality") net assets increased from US\$4,455,553,398 as at 30 September 2024 to US\$6,605,390,654 as at 30 September 2025. No other Fund within the Company has been registered in Switzerland as at 30 September 2025.

For further information please see the Investment Manager's Report on page 10.

**Directors**

The Directors who held office during the financial year were:

Mr. David Bohan (United States)  
Ms. Eimear Cowhey (Ireland)  
Mr. Arron Day (United Kingdom)  
Mr. John Fitzpatrick (Ireland)

---

**GMO FUNDS PLC**  
**DIRECTORS' REPORT (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**Directors (continued)**

All of the above-mentioned Directors held office throughout the financial year.

**Principal Activities**

The Company is an open-ended investment company with variable capital organised under the laws of Ireland. The Company is organised in the form of an umbrella fund with segregated liability between sub-funds.

The Company is authorised by the Central Bank of Ireland (the “Central Bank”) as an Undertaking for Collective Investment in Transferable Securities in accordance with the provisions of the UCITS Regulations.

**Results**

The results for the financial year are stated in the Statement of Comprehensive Income on page 16.

**Secretary**

Bradwell Limited (the “Secretary”) is the Secretary of the Company and held the position for the full financial year.

**Directors' and Secretary's Interests**

The Directors were not aware that they or their families have any interest in the shares of the Funds as at 30 September 2025 or as at 30 September 2024, other than in respect of the following Directors who each held one non-participating subscriber share:

**30 September 2025**

Mr. David Bohan  
Mr. Arron Day

**30 September 2024**

Mr. David Bohan  
Mr. Arron Day

The Secretary was not aware that it has any interest in the shares of the Funds as at 30 September 2025 or as at 30 September 2024.

**Dividends**

GMO Quality Investment Fund declared dividends during the financial years ended 30 September 2025 and 30 September 2024. Please see the Dividend Policy within the Notes to the Financial Statements for more information.

**Corporate Governance Statement**

The Board of Directors has assessed the measures included in the voluntary Corporate Governance Code for Collective Investment Schemes and Management Companies as published by the Irish Funds (“IF”) in December 2011 (the “IF Code”). The Board of Directors has adopted all corporate governance practices and procedures in the IF Code with effect from 31 December 2012. The Board of Directors considers that the Company has complied with the main provisions contained in the IF Code from the start of the fiscal year to 30 September 2025.

**Risk Management Objectives**

There can be no assurance that any Fund will achieve its investment objective. The value of shares may rise or fall as the capital value of the securities in which the Fund invests may fluctuate. The main risks arising from the Funds' investments in financial instruments are detailed in Note 9 to the financial statements.

**Audit Committee**

The Company has not established an audit committee. Given the internal organisation of the Company, the nature, scope and complexity of the Company's activities and the existing processes and procedures adopted by the Company, the Board does not consider that an audit committee is required for the purposes of Section 167 of the Companies Act 2014.

---

**GMO FUNDS PLC**  
**DIRECTORS' REPORT (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**Significant Events During the Financial Year**

On 8 October 2024, the Company issued a second supplemental prospectus to create seven new share classes in Quality, namely Class G USD, Class G EUR, Class GH SGD, Class GH AUD, Class M USD Distributing, Class M GBP Distributing and Class N USD.

On 7 November 2024, the Company issued a third supplemental prospectus to create ten new share classes in Quality, namely Class JH EUR, Class JH CHF, Class M GBP, Class O USD, Class OH EUR, Class OH GBP, Class OH SGD, Class OH AUD, Class OH HKD and Class OH CHF.

On 10 February 2025, the Company issued a fourth supplemental prospectus to create one new share class in Quality, namely Class JU USD.

On 24 February 2025, the Company issued a fifth supplemental prospectus to create two new share classes in Quality, namely Class FN USD and Class FN EUR.

On 7 April 2025, the Company issued a sixth supplemental prospectus to create five new share classes in Quality, namely Class GBP Distributing, Class USD Distributing, Class JH GBP, Class JH CNH and Class OH CNH.

On 11 June 2025, the Company issued a seventh supplemental prospectus to modify the manner in which the Class DH NOK Share Class of Quality is hedged.

On 18 July 2025, the Company issued an eighth supplemental prospectus to create one new share class in Quality, namely, Class E USD Distributing.

There were no other significant events during the financial year requiring financial statement disclosure.

**Significant Events Since the Financial Year End**

On 8 December 2025, the Company issued a ninth supplemental prospectus to create one new share class in Quality, namely, Class P NOK.

There were no other significant events occurring since the financial year end requiring financial statement disclosure.

**Independent Auditors**

The auditors, PricewaterhouseCoopers, have indicated their willingness to continue in office in accordance with Section 383(2) of the Companies Act 2014.

**Date: 18 December 2025**

---

**GMO FUNDS PLC**  
**REMUNERATION POLICY FOR THE INVESTMENT MANAGER (UNAUDITED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

In line with the requirements of the UCITS Regulations, the Company has adopted a remuneration policy (the “Remuneration Policy”).

The Directors who are not employees of the Investment Manager or an affiliate (the “Independent Directors”) receive a fixed annual fee which is competitive and based on the individual Director’s powers, tasks, expertise and responsibilities. Directors that are employees of the Investment Manager or an affiliate are not paid any fees for their services as Directors.

For the financial year ended 30 September 2025, only the Independent Directors received a fixed fee from the Company in their roles as directors, which was in the aggregate £70,431. None of the directors are entitled to receive any variable remuneration from the Company.

No remuneration has been paid to staff of the Investment Manager by the Company. Instead, the Company pays an investment management fee to the Investment Manager. The Investment Manager pays remuneration to its staff in accordance with the policies, procedures and processes applicable to it.

In accordance with Regulation 89(3A)(d) and (e) of the UCITS Regulations, the policy and its implementation is reviewed at least annually and it is confirmed that no material changes have been made to the Remuneration Policy since its adoption. On 10 November 2016, the Company adopted an updated remuneration policy to reflect the provisions of ESMA’s Guidelines on Sound Remuneration Policies under the UCITS V Directive and other general non-material updates.



---

**GMO FUNDS PLC**  
**REMUNERATION POLICY FOR THE MANAGER (UNAUDITED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

The Manager has designed and implemented a remuneration policy (the “Policy”) in line with the provisions of S.I. 257 of 2013 European Union (Alternative Investment Fund Managers) Regulations 2013 (the “AIFM Regulations”), S.I. 352 of 2011 European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended) (the “UCITS Regulations”) and of the ESMA Guidelines on sound remuneration policies under the UCITS Directive and AIFMD (the “ESMA Guidelines”). The Policy is designed to ensure that the remuneration of key decision makers is aligned with the management of short and long-term risks, including the oversight and where appropriate the management of sustainability risks in line with the Sustainable Finance Disclosure Regulations.

The Manager’s remuneration policy applies to its identified staff whose professional activities might have a material impact on the Company’s risk profile and so covers senior management, risk takers, control functions and any employees receiving total remuneration that takes them into the same remuneration bracket as senior management and risk takers and whose professional activities have a material impact on the risk profile of the Company. The Manager’s policy is to pay identified staff a fixed component with the potential for identified staff to receive a variable component. It is intended that the fixed component will represent a sufficiently high proportion of the total remuneration of the individual to allow the Manager to operate a fully flexible policy, with the possibility of not paying any variable component. When the Manager pays a variable component as performance related pay certain criteria, as set out in the Manager’s remuneration policy, must be adhered to. The various remuneration components are combined to ensure an appropriate and balanced remuneration package that reflects the relevant staff rank and professional activity as well as best market practice. The Manager’s remuneration policy is consistent with, and promotes, sound and effective risk management and does not encourage risk-taking which is inconsistent with the risk profile of the funds it manages.

These disclosures are made in respect of the remuneration policies of the Manager. The disclosures are made in accordance with the ESMA Guidelines.

Total remuneration (in EUR) paid to the identified staff of the Manager fully or partly involved in the activities of the Company that have a material impact on the Company’s risk profile during the financial year to 31 December 2024 (the Manager’s financial year):

<b>Fixed remuneration</b>	<b>EUR</b>
Senior Management	3,377,918
Other identified staff	-
<b>Variable remuneration</b>	
Senior Management	732,962
Other identified staff	-
<b>Total remuneration paid</b>	<b>4,110,880</b>

Number of identified staff – 20

Neither the Manager nor the Company pays any fixed or variable remuneration to identified staff of the Investment Manager.

There have been no material changes made to the Remuneration Policy or the Manager’s remuneration practices and procedures during the financial year.

---

**GMO FUNDS PLC**  
**STATEMENT OF DEPOSITARY RESPONSIBILITIES AND DEPOSITARY REPORT**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

### **Reports of the Depositary to the Shareholders**

We have enquired into the conduct of Waystone Management Company (IE) Limited as the Manager of GMO Funds Plc (the “Company”) and into the conduct of the Company itself for the financial year ended 30 September 2025, in our capacity as Depositary to the Company.

This report including the opinion has been prepared for and solely for the shareholders in the Company, in accordance with Regulation 34, (1), (3) and (4) in Part 5 of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended, (the “UCITS Regulations”), and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown.

### **Responsibilities of the Depositary**

Our duties and responsibilities are outlined in Regulation 34, (1), (3) and (4) in Part 5 of the UCITS Regulations. One of those duties is to enquire into the conduct of the Company in each annual accounting period and report thereon to the shareholders.

Our report shall state whether, in our opinion, the Company has been managed in that financial year in accordance with the provisions of the Company’s constitution (the “Constitution”) and the UCITS Regulations. It is the overall responsibility of the Company to comply with these provisions. If the Company has not so complied, we as Depositary must state why this is the case and outline the steps which we have taken to rectify the situation.

### **Basis of Depositary Opinion**


The Depositary conducts such reviews as it, in its reasonable opinion, considers necessary in order to comply with its duties as outlined in Regulation 34, (1), (3) and (4) in Part 5 of the UCITS Regulations and to ensure that, in all material respects, the Company has been managed:

- (i) in accordance with the limitations imposed on its investment and borrowing powers by the provisions of the Constitution and UCITS Regulations;
- (ii) otherwise in accordance with the Constitution and the appropriate regulations.

### **Opinion**

In our opinion, the Company has been managed during the financial year, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the Constitution, the UCITS Regulations and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the “Central Bank’s UCITS Regulations”); and
- (ii) otherwise in accordance with the provisions of the Constitution, the UCITS Regulations and the Central Bank’s UCITS Regulations.



**State Street Custodial Services (Ireland) Limited**  
**78 Sir John Rogerson’s Quay**  
**Dublin 2**  
**Ireland**

**18 December 2025**

# **Independent auditors' report to the Directors of GMO Funds plc**

## **Report on the audit of the non-statutory financial statements**

---

### **Opinion**

In our opinion, the non-statutory financial statements (the “financial statements”) of GMO Quality Investment Fund, a sub-fund of GMO Funds plc:

- give a true and fair view of the Fund’s assets, liabilities and financial position as at 30 September 2025 and of its results for the year then ended; and
- have been properly prepared in accordance with Generally Accepted Accounting Practice in Ireland (accounting standards issued by the Financial Reporting Council of the UK, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”).

We have audited the financial statements which comprise:

- the Statement of Financial Position of the Fund as at 30 September 2025;
  - the Statement of Comprehensive Income of the Fund for the year then ended;
  - the Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares of the Fund for the year then ended;
  - the Statement of Investments of the Fund as at 30 September 2025; and
  - the notes to the financial statements of the Fund, which include a description of the accounting policies.
- 

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (“ISAs (Ireland)”) including ISA (Ireland) 805.

Our responsibilities under ISAs (Ireland) are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Independence**

We remained independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, which includes IAASA’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

---

### **Conclusions relating to going concern**

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Fund’s ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the Fund’s ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

---

### **Reporting on other information**

The other information comprises all of the information in the Annual Report and Audited Financial Statements Dedicated to the Swiss Market other than the financial statements and our auditors’ report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to

conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

---

## **Responsibilities for the financial statements and the audit**

### *Responsibilities of the directors for the financial statements*

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view.

The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Fund's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Fund or to cease operations, or have no realistic alternative but to do so.

### *Auditors' responsibilities for the audit of the financial statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our audit testing might include testing complete populations of certain transactions and balances, possibly using data auditing techniques. However, it typically involves selecting a limited number of items for testing, rather than testing complete populations. We will often seek to target particular items for testing based on their size or risk characteristics. In other cases, we will use audit sampling to enable us to draw a conclusion about the population from which the sample is selected.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA website at:

[https://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description\\_of\\_auditors\\_responsibilities\\_for\\_audit.pdf](https://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf).

This description forms part of our auditors' report.

### *Use of this report*

This report, including the opinion, has been prepared for management purposes to assist the directors in discharging their obligations in reporting to the Swiss Financial Market Authority in respect of GMO Quality Investment Fund in accordance with our engagement letter dated 13 November 2025 and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come including without limitation under any contractual obligations of the Company, save where expressly agreed by our prior consent in writing.

---

## **Other matter**

We draw attention to the fact that these financial statements have not been prepared under section 290 of the Companies Act 2014 and are not the Company's statutory financial statements.



PricewaterhouseCoopers

Chartered Accountants

Dublin

18 December 2025

---

**GMO FUNDS PLC**  
**INVESTMENT MANAGER'S REPORT**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**GMO Quality Investment Fund**

**Performance Summary**

For the financial year ended 30 September 2025, GMO Quality Investment Fund (“Quality” or the “Fund”) Class A USD returned +9.67%, net of fees (+10.24% gross of fees), as compared with the MSCI World Index\* return of +17.25%.

**Investment Environment**

Relative to the MSCI World Index, sector allocation made a negative contribution during this period. The Information Technology (overweight) and Materials (underweight) allocations made the largest positive impact while Health Care (overweight) and Financials (underweight) detracted.

Technology stocks maintained their strong performance, building on the robust rally from the previous year. This momentum was further bolstered by announcements of multiple large-scale AI infrastructure projects. Major tech companies also reported impressive earnings growth, largely driven by AI-related services. The Fund has invested in several key sectors, including internet, software, and semiconductors, with holdings in companies like Oracle, TSMC, Lam Research, and Broadcom. However, it did not include NVIDIA, the prominent GPU manufacturer that has significantly contributed to the advancement of AI.

Conversely, the Health Care sector, where the Fund had an overweight position, faced significant challenges. While a risk-seeking market would naturally be unfavorable to healthcare, additional idiosyncratic factors caused that sector to perform unusually poorly.

Security selection within sector made a negative contribution. Selection results in Industrials and Communication Services made the largest positive impact. Information Technology and Consumer Staples detracted. Stock selection within sectors had a larger impact than sector allocation.

Oracle, Lam Research, and TSMC added to returns, while Constellation Brands, UnitedHealth, and Elevance detracted from returns.

**Outlook**

In 2025, markets were shaped by narrow leadership and persistent enthusiasm around Artificial Intelligence, even as economic indicators pointed to a softer underlying environment. The Fund remains focused on higher-quality businesses, particularly in Information Technology and Health Care, where we see encouraging signs of recovery as the sector emerges from the long post-Covid cycle. While AI continues to dominate market sentiment, we have taken a measured approach - realizing profits where valuations appear extended while holding names we believe can endure volatility and remain long-term winners. The recent broad sell-off in software appears overdone, and we view productivity gains from new technologies as broadly supportive for the sector. Despite ongoing uncertainty, there remain attractive opportunities across quality companies, and we believe the Fund's disciplined focus on valuation and fundamentals provides a solid foundation to navigate the year ahead.

**Grantham, Mayo, Van Otterloo & Co. LLC**

**53 State Street, 33rd Floor**

**Boston, Massachusetts**

**02109**

**USA**

**Investment Manager**

**October 2025**

\* Although the Fund does not seek to allocate its investments in line with, or seek to control risk relative to any securities market index or benchmark, a discussion of the Fund's performance relative to the MSCI World Index is included for comparative purposes only.

*The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities, as is required to be disclosed in accordance with Article 7 of Regulation (EU) 2020/852 of the European Parliament and of the Council of 18 June 2020 on the establishment of a framework to facilitate sustainable investments under the Sustainable Finance Disclosure Regulation (SFDR).*

**GMO FUNDS PLC**  
**GMO QUALITY INVESTMENT FUND**  
**STATEMENT OF INVESTMENTS**  
**AS AT 30 SEPTEMBER 2025**

Shares	Description	Value US\$	% of Net Asset Value
TRANSFERABLE SECURITIES LISTED ON AN OFFICIAL STOCK EXCHANGE OR TRADED ON A REGULATED MARKET UNLESS OTHERWISE NOTED			
<b>Equities (30 September 2024: 96.67%)</b>			
<b>Denmark (30 September 2024: Nil)</b>			
754,325	Novo Nordisk AS Class B	40,923,390	0.62
		<b>40,923,390</b>	<b>0.62</b>
<b>France (30 September 2024: 4.36%)</b>			
1,837,321	Dassault Systemes SE	61,550,107	0.93
149,749	LVMH Moet Hennessy Louis Vuitton SE	91,584,598	1.38
400,372	Safran SA	141,178,145	2.14
		<b>294,312,850</b>	<b>4.45</b>
<b>Germany (30 September 2024: 3.14%)</b>			
162,147	Knorr-Bremse AG	15,213,237	0.23
584,655	SAP SE	156,560,346	2.37
		<b>171,773,583</b>	<b>2.60</b>
<b>Netherlands (30 September 2024: 1.05%)</b>			
105,073	ASML Holding NV	102,237,847	1.55
		<b>102,237,847</b>	<b>1.55</b>
<b>Spain (30 September 2024: 0.67%)</b>			
588,644	Amadeus IT Group SA	46,686,818	0.71
		<b>46,686,818</b>	<b>0.71</b>
<b>Switzerland (30 September 2024: 2.60%)</b>			
1,005,873	Nestle SA	92,376,221	1.40
		<b>92,376,221</b>	<b>1.40</b>
<b>Taiwan (30 September 2024: 2.95%)</b>			
6,206,108	Taiwan Semiconductor Manufacturing Co. Ltd.	265,773,671	4.02
		<b>265,773,671</b>	<b>4.02</b>
<b>United Kingdom (30 September 2024: 7.20%)</b>			
4,235,682	Compass Group PLC	144,210,852	2.18
3,232,694	Diageo PLC	77,270,023	1.17
24,983,374	Haleon PLC	111,798,988	1.69
2,201,637	Unilever PLC	130,419,849	1.98
		<b>463,699,712</b>	<b>7.02</b>
<b>United States (30 September 2024: 74.70%)</b>			
1,521,995	Abbott Laboratories	203,856,010	3.09
619,257	Accenture PLC	152,708,776	2.31
1,287,450	Alphabet, Inc. Class A	312,979,095	4.74
639,421	Amazon.com, Inc.	140,397,669	2.13
1,115,569	Apple, Inc.	284,057,335	4.30
495,725	Broadcom, Inc.	163,544,635	2.48
283,473	Cigna Group	81,711,092	1.24
1,297,451	Coca-Cola Co.	86,046,950	1.30
701,065	Constellation Brands, Inc.	94,412,424	1.43
459,775	Elevance Health, Inc.	148,562,498	2.25

The accompanying notes form an integral part of these audited financial statements.

**GMO FUNDS PLC**  
**GMO QUALITY INVESTMENT FUND**  
**STATEMENT OF INVESTMENTS (CONTINUED)**  
**AS AT 30 SEPTEMBER 2025**

Shares/ Par Value <sup>†</sup>	Description	Value US\$	% of Net Asset Value
<b>TRANSFERABLE SECURITIES LISTED ON AN OFFICIAL STOCK EXCHANGE OR TRADED ON A REGULATED MARKET UNLESS OTHERWISE NOTED (CONTINUED)</b>			
<b>Equities (30 September 2024: 96.67%) (continued)</b>			
	<b>United States (30 September 2024: 74.70%) (continued)</b>		
127,987	Eli Lilly & Co.	97,654,081	1.48
363,459	Hilton Worldwide Holdings, Inc.	94,295,803	1.43
216,336	Intuitive Surgical, Inc.	96,751,949	1.47
1,215,446	Johnson & Johnson	225,367,997	3.41
69,949	KLA Corp.	75,446,991	1.14
1,778,011	Lam Research Corp.	238,075,673	3.60
1,119,502	Merck & Co., Inc.	93,959,803	1.42
402,299	Meta Platforms, Inc.	295,440,340	4.47
910,378	Microsoft Corp.	471,530,285	7.14
775,088	Oracle Corp.	218,057,354	3.30
330,701	Quest Diagnostics, Inc.	63,024,997	0.95
703,557	Salesforce, Inc.	166,743,009	2.53
865,978	Texas Instruments, Inc.	159,106,138	2.41
406,433	Thermo Fisher Scientific, Inc.	197,000,678	2.98
690,344	TJX Cos., Inc.	99,782,322	1.51
370,241	Tradeweb Markets, Inc.	41,089,346	0.62
3,214,380	U.S. Bancorp	155,350,985	2.35
1,034,175	Uber Technologies, Inc.	101,318,125	1.53
505,601	UnitedHealth Group, Inc.	174,584,025	2.64
461,253	Visa, Inc.	157,462,549	2.38
1,171,162	Wells Fargo & Co.	98,166,799	1.49
		<b>4,988,485,733</b>	<b>75.52</b>
<b>TOTAL EQUITIES</b>		<b>6,466,269,825</b>	<b>97.89</b>
<b>Debt Obligations (30 September 2024: 2.70%)</b>			
	<b>United States (30 September 2024: 2.70%)</b>		
	<b>U.S. Government (30 September 2024: 2.70%)</b>		
197,000,000	U.S. Treasury Floating Rate Note, 4.05%, due 31/07/27 <sup>(a)</sup>	196,844,339	2.98
		<b>196,844,339</b>	<b>2.98</b>
<b>TOTAL DEBT OBLIGATIONS</b>		<b>196,844,339</b>	<b>2.98</b>
<b>TOTAL TRANSFERABLE SECURITIES LISTED ON AN OFFICIAL STOCK EXCHANGE OR TRADED ON A REGULATED MARKET UNLESS OTHERWISE NOTED</b>			
		<b>6,663,114,164</b>	<b>100.87</b>

The accompanying notes form an integral part of these audited financial statements.



**GMO FUNDS PLC**  
**GMO QUALITY INVESTMENT FUND**  
**STATEMENT OF INVESTMENTS (CONTINUED)**  
**AS AT 30 SEPTEMBER 2025**

**EXCHANGE TRADED AND/OR OVER-THE-COUNTER FINANCIAL DERIVATIVE INSTRUMENTS**

**FORWARD CURRENCY CONTRACTS (30 September 2024: 0.02%)**

Settlement Date	Counterparty	Currency Sold	Currency Purchased	Net Unrealised Appreciation/ (Depreciation) US\$	% of Net Asset Value
31/10/25	MSCI	USD 83,838,980	EUR 71,565,100	398,018	0.01
31/10/25	MSCI	USD 47,997,149	GBP 35,859,900	287,002	0.01
31/10/25	MSCI	USD 44,298,961	NOK 443,584,300	166,849	0.00
31/10/25	MSCI	USD 12,143,305	AUD 18,562,900	164,391	0.00
31/10/25	SSB	USD 28,313,164	SGD 36,522,000	81,504	0.00
31/10/25	MSCI	USD 11,473,237	CHF 9,130,800	42,887	0.00
02/10/25	SSB	TWD 46,137,500	NOK 15,310,729	20,683	0.00
29/10/25	MSCI	USD 35,411,055	NOK 353,465,400	20,597	0.00
31/10/25	MSCI	USD 548,836	EUR 467,100	973	0.00
31/10/25	CITI	NOK 11,514,200	USD 1,154,661	454	0.00
31/10/25	GS	USD 135,902	HKD 1,056,700	5	0.00
02/10/25	SSB	TWD 5,455,800	NOK 1,780,404	(571)	(0.00)
31/10/25	BCLY	CHF 223,100	USD 280,605	(777)	(0.00)
29/10/25	MSCI	DKK 2,737,700	NOK 4,294,762	(1,256)	(0.00)
02/10/25	SSB	NOK 16,904,751	TWD 51,593,300	(1,432)	(0.00)
31/10/25	SSB	TWD 51,593,300	NOK 16,901,152	(2,392)	(0.00)
29/10/25	SSB	CHF 684,400	NOK 8,584,246	(2,492)	(0.00)
29/10/25	MSCI	EUR 3,777,600	NOK 44,211,263	(14,183)	(0.00)
29/10/25	SSB	GBP 2,819,300	NOK 37,671,527	(19,828)	(0.00)
<b>Total Forward Currency Contracts (Gain)</b>				<b>1,183,363</b>	<b>0.02</b>
<b>Total Forward Currency Contracts (Loss)</b>				<b>(42,931)</b>	<b>(0.00)</b>
<b>TOTAL FORWARD CURRENCY CONTRACTS (NET)</b>				<b>1,140,432</b>	<b>0.02</b>

<b>TOTAL EXCHANGE TRADED AND/OR OVER-THE-COUNTER FINANCIAL DERIVATIVE INSTRUMENTS</b>	<b>1,140,432</b>	<b>0.02</b>
---	------------------	-------------

As at 30 September 2025, for the above contracts and/or agreements, the Fund had sufficient cash and/or securities to cover commitments or collateral requirements, if any, of the relevant broker or exchange.

	Value US\$	% of Net Asset Value
Total financial assets at fair value through profit or loss	6,664,297,527	100.89
Total financial liabilities at fair value through profit or loss	(42,931)	(0.00)
Other liabilities in excess of assets	(58,863,942)	(0.89)
<b>Net assets attributable to holders of redeemable participating shares</b>	<b>6,605,390,654</b>	<b>100.00</b>

The accompanying notes form an integral part of these audited financial statements.



---

**GMO FUNDS PLC**  
**GMO QUALITY INVESTMENT FUND**  
**STATEMENT OF INVESTMENTS (CONTINUED)**  
**AS AT 30 SEPTEMBER 2025**

---

	% of Total Asset Value
<b>Analysis of Total Assets</b>	
Transferable securities listed on an official stock exchange unless otherwise noted	96.69
Transferable securities traded on a regulated market unless otherwise noted	2.94
Over-the-counter financial derivative instruments	0.02
	<u><b>99.65</b></u>

<sup>†</sup> Denominated in U.S. Dollar, unless otherwise indicated.

<sup>(a)</sup> All or a portion of this security has been pledged to cover margin requirements on futures and/or cleared swap contracts, collateral on OTC swap contracts, forward currency contracts, written options, repurchase agreements and/or reverse repurchase agreements, if any.

For a listing of definitions of acronyms, counterparty and currency abbreviations used throughout the Statement of Investments, if any, please refer to page 15.

The accompanying notes form an integral part of these audited financial statements.

---

**GMO FUNDS PLC**  
**PORTFOLIO, COUNTERPARTY AND CURRENCY ABBREVIATIONS**  
**AS AT 30 SEPTEMBER 2025**

---

**Counterparty Abbreviations:**

BCLY	Barclays Bank PLC
CITI	Citibank N.A.
GS	Goldman Sachs International
MSCI	Morgan Stanley & Co. International PLC
SSB	State Street Bank and Trust Company
AUD	Australian Dollar
CHF	Swiss Franc
EUR	Euro
GBP	British Pound Sterling
HKD	Hong Kong Dollar
NOK	Norwegian Krone
SGD	Singapore Dollar
TWD	New Taiwan Dollar
USD	United States Dollar

The accompanying notes form an integral part of these audited financial statements.

**GMO FUNDS PLC**  
**STATEMENT OF COMPREHENSIVE INCOME**

	Notes	GMO Quality Investment Fund For the financial year ended 30 September 2025 US\$	GMO Quality Investment Fund For the financial year ended 30 September 2024 US\$
<b>Investment income</b>			
Interest income	2(e)	5,494,715	4,520,406
Dividend income	2(e)	76,906,743	40,582,256
Other income		4,882	-
Net gains/(losses) on financial assets and financial liabilities at fair value through profit or (loss)	2(b)	519,035,566	748,944,691
<b>Total investment income/(loss)</b>		<b>601,441,906</b>	<b>794,047,353</b>
<b>Operating expenses</b>			
Investment management fee	3	(25,927,248)	(12,905,183)
Manager's fees	3	(237,579)	(102,319)
Administration, depositary and transfer agent fees	3	(1,539,653)	(859,625)
Statutory audit fees	4	(75,301)	(35,579)
Legal fees		(355,002)	(229,390)
Directors' fees	3	(82,698)	(47,927)
Transaction fees	2(k), 3	(2,296,888)	(1,915,931)
Other expenses		(257,001)	(75,187)
<b>Total operating expenses</b>		<b>(30,771,370)</b>	<b>(16,171,141)</b>
Refund of value added tax	5	52,327	29,890
<b>Net profit/(loss) for the financial year before interest and tax</b>		<b>570,722,863</b>	<b>777,906,102</b>
<b>Finance costs</b>			
Interest paid		(706)	-
Distributions to redeemable participating shareholders		(2,463,703)	(1,418,395)
<b>Net profit/(loss) for the financial year before tax</b>		<b>568,258,454</b>	<b>776,487,707</b>
Withholding tax	2(e), 5	(17,581,262)	(9,628,724)
<b>Net increase/(decrease) in net assets attributable to holders of redeemable participating shares from operations</b>		<b>550,677,192</b>	<b>766,858,983</b>

Income and expense results arose solely from continuing operations. There were no recognised gains or losses other than those included in the Statement of Comprehensive Income.

The accompanying notes form an integral part of these audited financial statements.

**GMO FUNDS PLC**  
**STATEMENT OF FINANCIAL POSITION**

		GMO Quality Investment Fund As at 30 September 2025 US\$	GMO Quality Investment Fund As at 30 September 2024 US\$
	Notes		
<b>Assets</b>			
Financial assets at fair value through profit or (loss)			
- Transferable securities		6,663,114,164	4,434,213,646
- Financial derivative instruments	2(b)	1,183,363	970,948
Cash at bank	2(h)	-	351,320
Dividends and interest receivable	2(e)	6,474,827	5,276,716
Subscriptions receivable		3,477,109	21,502,227
Receivable for investments sold		12,835,061	24,966,899
Tax reclaims receivable	5	357,035	70,694
Fund expense reimbursement receivable	3	2	2
<b>Total assets</b>		<b>6,687,441,561</b>	<b>4,487,352,452</b>
<b>Liabilities</b>			
Financial liabilities at fair value through profit or (loss)			
- Financial derivative instruments	2(b)	(42,931)	-
Bank overdraft	2(h)	(1,170,062)	-
Investment management fee payable	3	(2,728,333)	(1,670,031)
Manager's fee payable	3	(45,433)	(11,049)
Administration, depositary and transfer agent fees payable	3	(422,463)	(367,643)
Directors' fees payable	3	(22,553)	(13,690)
Payable for statutory audit fees		(77,545)	(35,226)
Withholding tax payable	5	(1,430,591)	(946,031)
Redemptions payable		(32,422,374)	(436,200)
Payable for investments purchased		(43,663,956)	(28,282,711)
Other payables		(24,666)	(36,473)
<b>Total liabilities (excluding net assets attributable to holders of redeemable participating shares)</b>		<b>(82,050,907)</b>	<b>(31,799,054)</b>
<b>Net assets attributable to holders of redeemable participating shares</b>	14	<b>6,605,390,654</b>	<b>4,455,553,398</b>

The accompanying notes form an integral part of these audited financial statements.

---

**GMO FUNDS PLC**  
**STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES**

---

		GMO Quality Investment Fund For the financial year ended 30 September 2025 US\$	GMO Quality Investment Fund For the financial year ended 30 September 2024 US\$
	Notes		
Net assets attributable to holders of redeemable participating shares at the beginning of the financial year		<u>4,455,553,398</u>	<u>1,389,860,736</u>
Net increase/(decrease) in net assets resulting from operations attributable to holders of redeemable participating shares		550,677,192	766,858,983
<b>Capital transactions</b>			
Net proceeds from redeemable participating shares issued	13	3,695,907,722	2,858,918,222
Net payment for redeemable participating shares redeemed	13	<u>(2,096,747,658)</u>	<u>(560,084,543)</u>
Net assets attributable to holders of redeemable participating shares at the end of the financial year	14	<u><u>6,605,390,654</u></u>	<u><u>4,455,553,398</u></u>

The accompanying notes form an integral part of these audited financial statements.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

## **1. Organisation and structure**

GMO Funds Plc (the “Company”) is an open-ended investment company with variable capital organised under the laws of Ireland as a public limited company pursuant to the Companies Act 2014 and the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011, as amended (the “UCITS Regulations”) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the “Central Bank UCITS Regulations”). It is an umbrella fund with segregated liability between sub-funds (each, a “Fund” and together, the “Funds”). It was incorporated on 19 December 2001 under registration number 351477. The assets of each Fund are separate from one another and are invested separately in accordance with the investment objectives and policies of each Fund. Any liability incurred on behalf of, or attributable to, any Fund shall be discharged solely out of the assets of that Fund. These financial statements include the following Fund, GMO Quality Investment Fund (“Quality”), which commenced operations on 10 November 2010.

The investment strategy employed by the Fund and the risks related to an investment in the Fund are discussed in detail in the Company’s prospectus.

Quality is currently distributed in Switzerland. The distribution of shares in Switzerland will be exclusively made to, and directed at, qualified investors as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended and its implementing ordinance.

## **2. Summary of significant accounting policies**

### **(a) Statement of Compliance**

These annual audited financial statements have been prepared in accordance with Financial Reporting Standard (“FRS”) 102, the financial reporting standard applicable in the UK and the Republic of Ireland (“FRS 102”), Irish statute comprising the Companies Act 2014 and the UCITS Regulations.

The format and wording of certain line items on the primary statements contain departures from the guidelines under the Companies Act 2014 to reflect this Company’s structure as an investment fund.

The financial statements are prepared under the historical cost convention as modified by the revaluation of financial assets and financial liabilities held at fair value through profit or loss. All references to net assets throughout this document refer to net assets attributable to holders of redeemable participating shares unless otherwise stated.

The Company has availed of the exemption available to open ended investment funds that hold a substantial proportion of highly liquid and fair valued investments under Section 7 of FRS 102 and is not presenting a cash flow statement.

### **(b) Financial assets and financial liabilities at fair value through profit or loss**

#### *(i) Classification*

The Fund has designated all of its investments as financial assets and financial liabilities at fair value through profit or loss.

This category has two sub-categories: financial assets and financial liabilities held for trading, and those designated by the Directors at fair value through profit or loss at inception. Financial assets or financial liabilities held for trading are acquired or incurred principally for the purpose of selling or repurchasing in the short-term. In addition, derivatives are categorised as held for trading, as the Fund does not designate any derivatives as hedges in a hedging relationship as defined by authoritative guidance.

#### *(ii) Recognition/derecognition*

Financial assets and financial liabilities are accounted for on the trade date (i.e., the date on which the transaction takes place) for financial reporting purposes. Financial assets and financial liabilities are derecognised when the rights to receive or duty to pay cash flows from the financial assets and financial liabilities have expired or the Fund has transferred substantially all risks and rewards of ownership. In determining the net gain or loss on securities sold, the Fund uses the identified cost method for the purpose of determining cost.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**2. Summary of significant accounting policies (continued)**

**(b) Financial assets and financial liabilities at fair value through profit or loss (continued)**

*(iii) Measurement*

Financial assets and financial liabilities at fair value through profit or loss are recognised at fair value. Transaction costs, if any, are expensed in the Statement of Comprehensive Income. Gains and losses arising from changes in the fair value of the financial assets or financial liabilities at fair value through profit or loss category are presented in the Statement of Comprehensive Income in the financial year in which they arise.

*(iv) Fair value estimation*

The fair value of assets listed or traded on a regulated market (other than exchange-traded options) for which market quotations are readily available shall be valued at the last traded price on the regulated market which is the principal market for such securities at the Statement of Financial Position date. If the last traded price is unavailable, then the official closing price shall be used. If, in turn, the official closing price is unavailable, then the last bid price shall be used. Exchange-traded options are valued at the last sale price, provided that price is between the closing bid and ask prices. If the last sale price is not within that range, then they will be valued at the closing bid price for long positions and the closing ask price for short positions.

Some exchange-traded derivatives, such as futures contracts, shall be valued at the relevant settlement price at the Statement of Financial Position date on the appropriate exchange for such instruments. Cleared derivatives are valued using the price quoted (which may be based on a model) by the relevant clearing house. If an updated quote for a cleared derivative is not available by the time that a Fund calculates its net asset value ("NAV") on any business day, then that derivative will generally be valued using an industry standard model, which may differ from the model used by the relevant clearing house. Over-the-counter ("OTC") derivatives are generally valued at the price determined by an industry standard model. In the case of derivatives, prices determined by a model may reflect an estimate of the average of bid and ask prices regardless of whether a Fund has a long position or a short position.

Typically, the Fund values fixed income securities at the most recent price supplied by a pricing source determined by State Street Fund Services (Ireland) Limited (the "Administrator") in consultation with Grantham, Mayo, Van Otterloo & Co. LLC (the "Investment Manager" or "GMO LLC"). The Investment Manager evaluates pricing sources on an ongoing basis and may change a pricing source at any time. The Investment Manager monitors erratic or unusual movements (including unusual inactivity) in the prices supplied for a security and may recommend to the Administrator that it override a price supplied by a source (e.g., by taking a price supplied by another), when it believes that the price supplied is not reliable. Alternative pricing sources are often but not always available for securities held by the Fund.

Cash and other liquid assets will be valued at their face value with interest accrued, which approximates fair value. Units or shares in collective investment schemes will be valued at the latest available unaudited NAV relevant to the collective investment scheme.

In the event of it being impossible or incorrect to carry out a valuation of a specific investment in accordance with the valuation rules set out in the preceding paragraphs, or if such valuation is not representative of a security's fair market value, the Administrator (in consultation with the Investment Manager) is entitled to use such other generally recognised valuation method in order to reach a proper valuation of that specific instrument, provided that such method of valuation has been approved by State Street Custodial Services (Ireland) Limited (the "Depositary") and the rationale for the use of such method of valuation and the method itself used shall be clearly documented. Also, the Directors, with the approval of the Depositary, may adjust the value of an asset where such an adjustment is considered necessary to reflect the fair value of such asset in the context of currency, marketability, dealing costs and/or such other considerations as the Directors deem relevant. The Directors' intention is only to exercise this discretion to preserve the value of a Fund's assets.

Because of the uncertainty inherent in pricing, and in particular fair value pricing, the value determined for a particular security may be materially different from the value realised upon its sale.

*(v) Derivative instruments*

The Fund may, from time to time, hold financial instruments that are not quoted in active markets, such as OTC derivatives. Derivatives are financial contracts whose value depends on, or is derived from, the value of underlying assets, reference rates, or indices that are used to increase, decrease or adjust elements of the investment exposures of a Fund's portfolio. Derivatives may relate to securities, interest rates, currencies, currency exchange rates, inflation rates, commodities and indices, and include foreign currency contracts, swap contracts, and other exchange-traded and OTC contracts.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**2. Summary of significant accounting policies (continued)**

**(b) Financial assets and financial liabilities at fair value through profit or loss (continued)**

*(v) Derivative instruments (continued)*

*Forward currency contracts*

The Fund may enter into forward currency contracts, including forward cross-currency contracts. A forward currency contract is an agreement between two parties to buy and sell a currency at a set price on a future date (or to pay or receive the amount of the change in relative values of the two currencies). The market price of a forward currency contract fluctuates with changes in forward currency exchange rates.

The value of each of the Fund forward currency contracts is marked-to-market daily using rates supplied by a quotation service and changes in value are recorded by each Fund as unrealised gains or losses. Realised gains or losses on the contracts are equal to the difference between the value of the contract at the time it was opened and the value at the time it was settled.

These contracts involve market risk in excess of the unrealised gain or loss. Forward currency contracts expose the Fund to the market risk of unfavourable movements in currency values and the risk that the counterparty will be unable or unwilling to meet the terms of the contracts. Most forward currency contracts are collateralised. Forward currency contracts outstanding at the end of the financial year, if any, are listed in each applicable Fund's Statement of Investments.

*Share class hedges*

The Fund also enters into class level hedging in order to hedge against currency exposure at a class level. For class level hedges the fair value of the hedge is calculated in a similar manner to the portfolio hedges. However, the realised and unrealised gains or losses are allocated solely to the relevant share classes of the Fund. Unrealised gains or losses on open share class hedges are reported as part of financial derivative instruments in the Statements of Financial Position.

The Fund held derivatives during the financial year ended 30 September 2025, the following table shows how the Fund used these derivatives (marked with an X):

Type of Derivative and Objective for Use	Quality
<b>Share class hedges</b>	
Hedge against currency exposure at a class level	X

**(c) Accounting estimates and assumptions**

The preparation of financial statements, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the financial year. Actual results could differ from those estimates and these differences could be material.

**(d) Foreign currency translation**

*Functional and presentation currency*

Items included in the Fund's financial statements are measured using the currency of the primary economic environment in which the Fund operates (the "functional currency"), which is the U.S. Dollar. The presentation currency of the Fund is also the U.S. Dollar.

*Transactions and balances*

The fair values of foreign securities, currency holdings and other assets and liabilities are translated into the functional currency of the Fund based on the prevailing exchange rates on each business day. Income and expenses denominated in other currencies are translated at prevailing exchange rates when accrued or incurred. The Fund does not isolate realised and unrealised gains and losses attributable to changes in exchange rates from gains and losses that arise from changes in the fair value of investments. Such fluctuations are included within net gains/(losses) on financial assets and financial liabilities at fair value through profit or loss within the Statement of Comprehensive Income.



---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**2. Summary of significant accounting policies (continued)**

**(d) Foreign currency translation (continued)**

*Transactions and balances (continued)*

Net realised gains and losses on foreign currency transactions represent net exchange gains and losses on disposal of foreign currencies, currency gains and losses realised between the trade and settlement dates on securities transactions, and the difference between the amount of investment income and foreign withholding taxes, if any, recorded on the Fund's books and the U.S. Dollar equivalent amounts actually received or paid.

**(e) Income**

Dividends are recognised as income on the dates on which the securities are listed ex-dividend or, if later, when the Fund is informed of the ex-dividend date. Interest income is accounted for on an accrual basis, if any. Income is shown gross of withholding taxes, which are separately disclosed in the Statement of Comprehensive Income.

Premiums or discounts on the purchase of fixed and variable interest investments are amortised over the life of the investment on an effective yield basis where appropriate. The effective interest rate is the rate that discounts estimated future cash payments or receipts throughout the expected life of the financial instrument, or a shorter period where appropriate, to the net carrying amount of the financial asset or financial liability. Coupon income is not recognised on securities for which collection is not expected.

**(f) Collective investment schemes**

The Fund may, subject to the limits set out in the prospectus, be invested in collective investment schemes which are UCITS or UCITS Equivalent Schemes. Such investment in collective investment schemes includes investing in other funds (i.e., other sub-funds of the Company). However, the Fund may not invest in another Fund which itself holds shares in other Funds. Where a Fund invests in another Fund, the investing Fund may not charge an annual management and/or investment management fee in respect of the portion of its assets invested in the other Fund. Collective investment schemes outstanding at the end of the financial year, if any, are listed in each applicable Fund's Statements of Investments.

**(g) Dilution adjustment**

In calculating the net asset value per share for each class on any dealing day, the Investment Manager may, at its discretion, adjust the net asset value per share for each class by applying a dilution adjustment: (1) if net subscriptions or redemptions exceed certain pre-determined percentage thresholds relating to the Fund's net asset value (where such percentage thresholds have been pre-determined for the Fund from time to time by the Investment Manager or by a committee established by the Investment Manager); or (2) in any other cases where there are net subscriptions or redemptions in the Fund and the Investment Manager reasonably believes that imposing a dilution adjustment is in the best interests of existing shareholders.

Absent a dilution adjustment, the price at which the subscriptions or redemptions are affected would not reflect the costs of dealing in the underlying investments of the Fund including subscription and redemption charges applicable at the level of the Fund. Such costs could have a materially disadvantageous effect on the interests of existing shareholders in the Fund.

There was no such adjustment for the Fund as at 30 September 2025 or 30 September 2024.

**(h) Cash at bank and bank overdraft**

All cash at bank balances and bank overdrafts are held with the Depositary, or with third party institutions approved by the Company on overnight deposit, or directly with a sub-custodian. Cash held on overnight deposit, if any, with the respective counterparties is detailed as part of the Statements of Investments for the Fund.

**(i) Redeemable participating shares**

Redeemable participating shares are generally redeemable at the shareholder's option on dealing days as set forth in the prospectus and are classified as financial liabilities. The value of the redeemable participating shares of the Fund shall at all times equal the NAV of the Fund.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**2. Summary of significant accounting policies (continued)**

**(j) Dividend policy**

The Company may issue distributing and non-distributing classes of shares. Unless otherwise stated below, it is not the current intention of the Directors to declare a dividend in respect of any class of shares of the Fund, but rather to reinvest all income and capital gains. However, the Directors may, upon advance notice to shareholders, decide to change the dividend policy of, and declare a dividend in respect of, any class of shares in the Fund. Where such dividend is declared, it may be paid out of dividend and net interest income earned plus net realised and net unrealised capital gains after the deduction of expenses in that accounting period attributable to the relevant class.

The Company will declare dividends semi-annually in respect of the below Fund's classes.

**Quality**

Class C EUR Distributing  
Class C GBP Distributing  
Class C USD Distributing  
Class E USD Distributing  
Class F EUR Distributing  
Class F GBP Distributing  
Class F USD Distributing  
Class M GBP Distributing  
Class M USD Distributing

Payment will be made to shareholders who held shares on 31 March and/or 30 September in the relevant year (or in the event that 31 March and 30 September in any year does not fall on a business day, the business day preceding that date). The dividends shall be paid within eight weeks of the ex-dividend date out of dividend and net interest income earned after the deduction of expenses and taxes in that accounting period attributable to the relevant class. Shareholders may agree with the Investment Manager to automatically re-invest dividends. Quality declared dividends during the financial years ended 30 September 2025 and 30 September 2024.

Dividends declared or paid by the Fund are recorded by the Fund on the ex-dividend date and are disclosed separately in the Statement of Comprehensive Income as a finance cost. The following distributions to holders of redeemable participating shares were paid during the twelve-months ended 30 September 2025.

<b>Quality</b>	<b>Ex-Date</b>	<b>Distributions to holders of redeemable participating shares US\$</b>
Class C EUR Distributing	1 October 2024	31,438
Class C EUR Distributing	1 April 2025	23,916
Class C GBP Distributing	1 October 2024	3,259
Class C GBP Distributing	1 April 2025	2,545
Class C USD Distributing	1 October 2024	799,784
Class C USD Distributing	1 April 2025	605,868
Class F EUR Distributing	1 April 2025	1,972
Class F GBP Distributing	1 April 2025	42,687
Class F USD Distributing	1 April 2025	43,776
Class M GBP Distributing	1 April 2025	908,438
Class M USD Distributing	1 April 2025	20

The following distributions to holders of redeemable participating shares were paid during the twelve-months ended 30 September 2024.

<b>Quality</b>	<b>Ex-Date</b>	<b>Distributions to holders of redeemable participating shares US\$</b>
Class C EUR Distributing	2 October 2023	712
Class C EUR Distributing	2 April 2024	17,642

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**2. Summary of significant accounting policies (continued)**

**(j) Dividend policy (continued)**

Quality	Ex-Date	Distributions to holders of redeemable participating shares US\$
Class C GBP Distributing	2 October 2023	2,408
Class C GBP Distributing	2 April 2024	2,786
Class C USD Distributing	2 October 2023	672,775
Class C USD Distributing	2 April 2024	722,072

There were no dividends declared in respect of Quality Class E USD Distributing for the financial year ended 30 September 2025. There were no dividends declared in respect of Quality Class F EUR Distributing, Class F GBP Distributing, Class F USD Distributing, Class M GBP Distributing and Class M USD Distributing for the financial year ended 30 September 2024.

**(k) Transaction fees**

The Fund incurs transaction fees comprising of brokerage fees and other transaction fees relating to purchases and sales of transferable securities, collective investment schemes and financial derivative instruments. These fees, if any, are recognised as an expense in the Statement of Comprehensive Income.

**(l) Due to/from broker**

Due to/from broker, if any, includes cash for swap contracts, futures contracts, option contracts and forward currency contracts, if any, which relates to collateral or margin held by the Fund or with the relevant broker. For details on collateral positions held with the relevant brokers, see Note 7.

**3. Fees**

Each Fund of the Company shall pay all of its expenses and its allocable share of any expenses incurred by the Company. These expenses may include the costs of: (i) maintaining the Company and the relevant Fund and registering the Company, the relevant Fund and the shares with any governmental or regulatory authority or with any regulated market or stock exchange; (ii) management, administration, depositary and related services; (iii) preparation, printing and posting of prospectuses, sales literature and reports to shareholders, the Central Bank and other governmental agencies; (iv) marketing expenses; (v) taxes; (vi) commissions and brokerage fees; (vii) expenses incurred in connection with the acquisition and disposal of the assets of the Company; (viii) auditing, tax and legal fees (including expenses arising in respect of legal or administrative proceedings); (ix) insurance premiums and (x) other operating expenses.

As a shareholder of another collective investment scheme, each Fund of the Company would bear, along with other shareholders, its pro rata portion of the expenses of the other collective investment scheme, including management and/or other fees. The maximum level of management fees (exclusive of any performance fee) which may be charged to a collective investment scheme in which a Fund invests is 2.5 per cent. of the NAV of that scheme. These fees would be in addition to the management fees and other expenses which a Fund bears directly in connection with its own operations.

*Administration, depositary and transfer agent fees*

The Company pays to the Administrator, out of the assets of each Fund of the Company, an annual fee of 2.5 basis points of the NAV up to US\$500 million, 2 basis points of the NAV for the next US\$500 million, 1.5 basis points of the NAV for the next US\$500 million and any excess of this at 1 basis point of the NAV. There is no minimum fee applied, as stated in the fee schedule. The Company also pays to the Administrator, for transfer agency services, an annual fee of US\$15,000. The Company also pays the Administrator, for financial reporting services, an annual fee of US\$5,000. Such fees are accrued on each dealing day and shall generally be paid monthly in arrears.

The Depositary is entitled to receive, out of the assets of each Fund of the Company an annual fee of 1.25 basis points of the NAV up to US\$500 million and any excess of this at 1 basis point of the NAV. The Company also pays the Depositary safekeeping and transaction fees which will vary from country to country but will be charged at normal commercial rates. These fees are accrued on each dealing day and shall generally be paid monthly in arrears.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**3. Fees (continued)**

*Administration, depositary and transfer agent fees (continued)*

The Company will apportion the Administrator's and Depositary's fees in which shares are available for purchase on the basis of the proportion of the actual fees accrued on each Fund of the Company. Each of the Depositary and the Administrator shall also be reimbursed for any out-of-pocket expenses incurred. In addition, the Depositary shall be entitled to be reimbursed for all sub-custodial fees and expenses it incurs, which will be charged at normal commercial rates. The tables below detail the fees charged during the financial years ended 30 September 2025 and 30 September 2024 and the amounts outstanding as at 30 September 2025 and 30 September 2024.

<b>For the financial year ended</b>	<b>Quality</b>
<b>30 September 2025</b>	<b>US\$</b>
Administration/transfer agent fees*	721,219
Depositary/transaction fees**	845,433
<b>Total</b>	<b><u>1,566,652</u></b>

<b>For the financial year ended</b>	<b>Quality</b>
<b>30 September 2024</b>	<b>US\$</b>
Administration/transfer agent fees*	442,125
Depositary/transaction fees**	444,054
<b>Total</b>	<b><u>886,179</u></b>

<b>As at 30 September 2025</b>	<b>Quality</b>
	<b>US\$</b>
Administration/transfer agent fees payable*	205,092
Depositary/transaction fees payable**	217,371
<b>Total</b>	<b><u>422,463</u></b>

<b>As at 30 September 2024</b>	<b>Quality</b>
	<b>US\$</b>
Administration/transfer agent fees payable*	178,934
Depositary/transaction fees payable**	188,709
<b>Total</b>	<b><u>367,643</u></b>

\* Amounts paid to the Administrator.

\*\* Amounts paid to the Depositary.

*Investment Manager's fee*

Each Fund of the Company pays the Investment Manager a management fee (the "Management Fee") in consideration for the Investment Manager's management of the Fund's portfolios, shareholder servicing, and other services which the Investment Manager and its affiliates (including GMO UK Limited and GMO Netherlands B.V.) provide to the Fund.

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**3. Fees (continued)**

*Investment Manager's fee (continued)*

The table below sets forth the maximum Management Fee and the threshold in excess of which Reimbursable Expenses (as defined below) will be reimbursed by the Investment Manager.

<b>Fund: Quality</b>	<b>Management Fee</b>	<b>Reimbursement Threshold</b>
Classes USD, GBP, EUR, SGD, AUD, HKD <sup>1</sup> , F USD, F EUR, FH EUR, FN USD, FN EUR, H EUR, H GBP, H NOK, H SGD <sup>1</sup> , O USD, OH EUR, OH GBP, OH SGD, OH AUD, OH HKD, OH CHF <sup>2</sup> and OH CNH <sup>1,2</sup>	Up to 0.48 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Classes USD Distributing <sup>1</sup> , GBP Distributing <sup>1</sup> , C EUR Distributing, C GBP Distributing, C USD Distributing, F EUR Distributing, F GBP Distributing, F USD Distributing, M GBP, M GBP Distributing, and M USD Distributing	Up to 0.48 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Classes DH NOK and D USD	Up to 0.44 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Classes E USD, E USD Distributing, E EUR, E NOK <sup>1</sup> and E GBP <sup>2</sup>	Up to 0.53 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Classes Z SGD, ZH SGD and Z USD <sup>1</sup>	0.00 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Class N USD <sup>1,2</sup>	Up to 0.60 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Classes G USD, G EUR, GH SGD, GH AUD, J USD, J GBP, J EUR, J SGD, J AUD, J HKD, JH GBP <sup>1</sup> , JH EUR, JH SGD, JH AUD, JH CHF, JH CNH <sup>1</sup> and JU USD <sup>2</sup>	Up to 1.00 per cent. of NAV per annum	0.10 per cent. of NAV per annum
Classes R EUR <sup>1</sup> , R USD, R SGD, RH SGD <sup>1</sup> and RH AUD <sup>1,2</sup>	Up to 1.10 per cent. of NAV per annum	0.10 per cent. of NAV per annum

<sup>1</sup> Class is offered but has no shareholders as at 30 September 2025.

<sup>2</sup> The investment management fee for the Class E, G, GH, J, JH, JU, N, O, OH, R and RH shares includes payments made by the Investment Manager to remunerate and/or pay trail or service fees to certain financial intermediaries.

The Management Fee is accrued on each dealing day and shall generally be paid monthly in arrears. The following table details the fees charged during the financial years ended 30 September 2025 and 30 September 2024 and the amounts outstanding as at 30 September 2025 and 30 September 2024.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**3. Fees (continued)**

*Investment Manager's fee (continued)*

	<b>Quality US\$</b>
For the financial year ended 30 September 2025	25,927,248
For the financial year ended 30 September 2024	12,905,183
	<b>Quality US\$</b>
As at 30 September 2025	2,728,333
As at 30 September 2024	1,670,031

The Investment Manager may reimburse each Fund of the Company for any Reimbursable Expenses (as defined below) that it incurs in any financial year, including its allocable portion of Reimbursable Expenses incurred by the Company, to the extent that such Reimbursable Expenses exceed such Fund's reimbursement threshold as set forth in the table above. "Reimbursable Expenses" include service fees incurred in connection with fund administration, custody of assets, distribution of the shares, compliance, transfer agency, corporate secretarial expenses and the expenses of convening shareholder meetings, ordinary legal and auditing matters, remuneration and expenses of the Directors (if any) and other reasonable expenses related to the foregoing. The following expenses are specifically excluded from Reimbursable Expenses: the Investment Management Fee, brokerage commissions and other investment-related costs, hedging transaction fees, extraordinary, non-recurring and certain other unusual expenses (including without limitation taxes and litigation expenses), securities lending fees and expenses, interest expense and transfer taxes. Subscription and repurchase charges, if any, are borne directly by shareholders and, accordingly, are also excluded from Reimbursable Expenses. The Investment Manager may modify or terminate this arrangement at any time upon notice to shareholders.

The Investment Manager is permitted to recover from a Fund, on a class-by-class basis, as applicable, any such reimbursement paid by them (whether through reduction of their fees or otherwise) to the extent that the Fund's Reimbursable Expenses later fall below the reimbursement threshold or the lower expense limit in effect when they seek to recover the expenses. The Fund, however, is not obligated to pay any such amount more than three years after the Investment Manager reimbursed an expense. The amount the Investment Manager is entitled to recover may not cause the Fund to exceed the reimbursement threshold or the lower expense limit in effect when the Investment Manager seeks recovery.

*Manager's fees*

Waystone Management Company (IE) Limited (the "Manager") serves as the Manager of the Company. Each Fund pays a management fee to the Manager in consideration for the services which the Manager provides to the Funds. The Manager shall receive a fee of up to 0.01 per cent. per annum of the NAV of the Fund subject to an annual minimum fee of €75,000 per annum. The following table details the fees charged during the financial years ended 30 September 2025 and 30 September 2024 and the amounts outstanding as at 30 September 2025 and 30 September 2024.

	<b>Quality US\$</b>
For the financial year ended 30 September 2025	237,579
For the financial year ended 30 September 2024	102,319
	<b>Quality US\$</b>
As at 30 September 2025	45,433
As at 30 September 2024	11,049

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

### 3. Fees (continued)

#### *Directors' fees*

The aggregate amount of Directors' remuneration in any one year shall not exceed €75,000 or such other amount as may be determined by the Directors and notified to shareholders from time to time. Any such change in the maximum aggregate amount of Directors' remuneration shall also be disclosed in an update to the prospectus or in the Company's financial statements, whichever is published sooner.

The Directors that are employees of the Investment Manager or GMO UK Limited do not intend to receive such remuneration. As such, the Directors who were in receipt of fees during the financial year were Ms. Eimear Cowhey and Mr. John Fitzpatrick.

### 4. Auditors' remuneration

The tables below outline the remuneration paid to the statutory auditors for the financial years ended 30 September 2025 and 30 September 2024.

<b>For the financial year ended</b>	<b>Quality</b>
<b>30 September 2025</b>	<b>US\$</b>
Statutory audit fees	75,301

<b>For the financial year ended</b>	<b>Quality</b>
<b>30 September 2024</b>	<b>US\$</b>
Statutory audit fees	35,579

Other than statutory audit fees, no other fees were paid to the auditors. Auditors out-of-pocket expenses for the financial year ended 30 September 2025 amounted to £1,777 (30 September 2024: £1,751).

### 5. Taxation

Under current law and practice the Company qualifies as an investment undertaking as defined in Section 739B of the Taxes Consolidation Act, 1997, as amended. On that basis, the Company is not chargeable to Irish tax on its income or gains.

However, Irish tax may arise on the happening of a "chargeable event". A chargeable event includes any distribution payments to shareholders, any encashment, redemption, cancellation or transfer of shares, and the holding of shares at the end of each eight year period beginning with the acquisition of such shares.

No Irish tax will arise on the Company in respect of chargeable events in respect of:

- (a) a shareholder who is neither Irish resident nor ordinarily resident in Ireland for tax purposes, at the time of the chargeable event, provided appropriate valid declarations in accordance with the provisions of the Taxes Consolidation Act, 1997, as amended, are held by the Company or the Company has been authorised by the Irish Revenue to make gross payments in the absence of appropriate declarations; and
- (b) certain exempted Irish tax resident shareholders who have provided the Company with the necessary signed declarations.

The Company may be subject to, and/or accrue, withholding, capital gains, transaction-based and other taxes imposed by certain jurisdictions on its investments. Taxes on foreign interest, dividend income and capital gains are generally withheld, assessed and/or accrued in accordance with the applicable country's tax treaty with Ireland and are recorded in the Statement of Comprehensive Income. There are some cases where the Company may not be able to benefit from reduced rates of withholding tax under the provisions of the double tax treaties which Ireland has entered into with various countries. Certain Funds have previously filed for and/or may file for additional tax refunds with respect to certain taxes withheld by member states of the European Union. Generally, the amounts of such refunds that a Fund reasonably determines to be collectible and free from significant contingencies are reflected in a Fund's NAV and are reflected as dividend income in the Statement of Comprehensive Income. Absent a determination that the amount of a refund is collectible and free from significant contingencies, such amount is not reflected in the Fund's NAV.



---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**5. Taxation (continued)**

In addition, the Company and/or shareholders may be subject to taxation and tax reporting obligations in jurisdictions in which the Funds make investments. The Company may seek to collect refunds in respect of taxes paid by the Funds to certain countries. In those cases, all or a portion of those taxes could ultimately be recovered. However, the recovery process could take several years and the Company will incur expenses in its efforts to collect such refunds, which will reduce the benefit to the relevant Fund of any recovery. The Company's efforts to collect a refund may not be successful, in which case the relevant Fund will have incurred additional expenses for no economic benefit. The Company's decision to pursue refunds is in its sole discretion, and it may decide not to pursue refunds, even if eligible.

**6. Exchange rates**

The following exchange rates (against the U.S. Dollar) were used to convert the assets and liabilities denominated in currencies other than the U.S. Dollar for Quality, as at 30 September 2025 and 30 September 2024:

<b>Currency</b>	<b>As at 30 September 2025</b>	<b>As at 30 September 2024</b>
Australian Dollar (AUD)	1.5089	1.4414
British Pound Sterling (GBP)	0.7428	0.7455
Danish Krone (DKK)	6.3528	6.6795
Euro (EUR)	0.8511	0.8960
Hong Kong Dollar (HKD)	7.7804	7.7675
New Taiwan Dollar (TWD)	30.4780	31.6465
Norwegian Krone (NOK)	9.9778	10.5327
Singapore Dollar (SGD)	1.2892	1.2820
Swiss Franc (CHF)	0.7957	0.8436

**7. Collateral**

When entering into an OTC derivative instrument and during the term of that transaction, the Fund and/or the counterparty may post or receive cash or securities as collateral related to changes in the market value of the derivative. Additionally, the counterparty may require additional collateral that is unrelated to changes in the market value of the derivative. Collateral may be rehypothecated by the party receiving the collateral. If the counterparty enters into insolvency proceedings or otherwise defaults on its obligations, the ability of the Fund to recover collateral posted to the counterparty may be delayed or limited.

Upon entering into an exchange-traded or cleared derivative instrument, the Fund is required to deposit cash, U.S. government or agency obligations or other liquid assets with the clearing broker in accordance with the initial margin requirements of the broker or exchange. The value of the Fund's exchange-traded or cleared derivative instruments is marked-to-market daily and an appropriate payable or receivable for the change in value ("variation margin") is recorded by each Fund. The payable or receivable is settled on the following business day.

**Collateral Pledged by Quality**

Cash Collateral and/or Margin Pledged

There was no cash collateral and/or margin pledged by Quality for OTC and/or exchange-traded positions as at 30 September 2025 or 30 September 2024.



**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**7. Collateral (continued)**

**Collateral Pledged by Quality (continued)**

Security Collateral Pledged

The nominal value and market value of the underlying securities pledged by Quality as collateral and/or margin to the counterparties as at 30 September 2025 were:

<b>Broker</b>	<b>Nominal Value US\$</b>	<b>Security Description</b>	<b>Value US\$</b>	<b>Collateralised Position</b>
Citibank N.A.	523,000	U.S. Treasury Floating Rate Note, 4.05%, 31/07/27	522,552	OTC
		<b>Total value</b>	<b><u>522,552</u></b>	

There were no underlying securities pledged by Quality as collateral and/or margin to the counterparties as at 30 September 2024.

**Collateral Pledged to Quality**

Cash Collateral and/or Margin Pledged

There was no cash collateral and/or margin pledged to Quality for OTC and/or exchange-traded positions as at 30 September 2025 or 30 September 2024.

Security Collateral Pledged

The nominal value and market value of the underlying securities pledged to Quality as collateral and/or margin to the counterparties as at 30 September 2025 were:

<b>Broker</b>	<b>Nominal Value US\$</b>	<b>Security Description</b>	<b>Value US\$</b>	<b>Collateralised Position</b>
Morgan Stanley & Co. International Plc	1,614,000	U.S. Treasury Note, 4.63%, due 15/02/35	1,677,299	OTC
State Street Bank and Trust Company	225,000	U.S. Treasury Note, 0.63%, due 31/07/26	219,238	OTC
		<b>Total value</b>	<b><u>1,896,537</u></b>	

The nominal value and market value of the underlying securities pledged to Quality as collateral and/or margin to the counterparties as at 30 September 2024 were:

<b>Broker</b>	<b>Nominal Value US\$</b>	<b>Security Description</b>	<b>Value US\$</b>	<b>Collateralised Position</b>
State Street Bank & Trust Company	202,000	U.S. Treasury Floating Rate Note, 0.63%, due 15/10/24	201,670	OTC
State Street Bank & Trust Company	773,000	U.S. Treasury Floating Rate Note, 0.25%, due 30/09/25	745,100	OTC
State Street Bank & Trust Company	1,392,000	U.S. Treasury Floating Rate Note, 2.25%, due 31/03/26	1,361,496	OTC
		<b>Total value</b>	<b><u>2,308,266</u></b>	

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

## **8. Fair value information**

### **Fair value hierarchy**

FRS 102 Section 11.27 on “Fair Value Disclosure” requires disclosure relating to the fair value hierarchy in which fair value measurements are categorised for assets and liabilities. The disclosures are based on a three-level fair value hierarchy for the inputs used in valuation techniques to measure fair value.

Financial assets and financial liabilities are measured in the Statement of Financial Position at fair value. The fair value measurements are categorised within a three-level hierarchy. The valuation hierarchy is based upon the relative observability and reliability of inputs to the valuation of each of the Fund’s investments. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The three levels are defined as follows:

Level 1 – The unadjusted quoted price in an active market for identical assets or liabilities that the entity can access at the measurement date.

The types of assets and liabilities categorised in Level 1 generally include actively traded domestic and certain foreign equity securities, certain U.S. government obligations, derivatives actively traded on a national securities exchange (such as some futures and options), and shares of open-end mutual funds (even if their investments are valued using Level 2 or Level 3 inputs).

Level 2 – Inputs other than quoted prices included within Level 1 that are observable (i.e., developed using market data) for the asset or liability, either directly or indirectly.

The types of assets and liabilities categorised in Level 2 generally include certain U.S. government agency securities, mortgage-backed securities, asset-backed securities, certain sovereign debt obligations, and corporate bonds valued using vendor prices or broker quotes; cleared derivatives and certain OTC derivatives such as swaps, options, swaptions, and forward currency contracts valued using industry standard models; certain restricted securities valued at the most recent available market or quoted price; certain rights and warrants; and certain securities that are valued at the local price.

Level 3 – Inputs are unobservable (i.e., for which market data is unavailable) for the asset or liability.

The types of assets and liabilities categorised in Level 3 generally include, but are not limited to, certain debt securities (such as asset-backed, mortgage-backed, loans and sovereign debt), closed-end funds and derivatives even though they may be valued using broker quotes; certain debt securities and derivatives adjusted by a specified discount for liquidity or other considerations; certain sovereign debt securities valued using comparable securities issued by the sovereign adjusted by a specified spread; securities whose trading has been suspended or that have been de-listed from their current primary trading exchange valued at the most recent available market or quoted price; securities in default or bankruptcy proceedings for which there is no current market quotation valued at the most recent available market or quoted price; certain equity securities valued off the last traded price with a discount for liquidity and certain securities that are valued using a price from a comparable security related to the same issuer.

The level in the fair value hierarchy within which the fair value measurement is categorised is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. The significance of an input is assessed against the fair value measurement in its entirety.

If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, this may be deemed to fall within Level 3 of the fair value hierarchy. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement and the consideration of factors specific to the asset or liability.

The determination of what constitutes “observable” requires significant judgement by the Investment Manager. The Investment Manager considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

The following tables analyse within the fair value hierarchy the financial assets and financial liabilities measured at fair value as at 30 September 2025 and 30 September 2024:

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**8. Fair value information (continued)**

**Fair value hierarchy (continued)**

**30 September 2025**

**Quality**

	Level 1 US\$	Level 2 US\$	Level 3 US\$	Total US\$
<b>Asset Valuation Inputs</b>				
<i>Financial assets at fair value through profit or loss:</i>				
Equities	6,466,269,825	-	-	6,466,269,825
Debt obligations				
U.S. government	196,844,339	-	-	196,844,339
Total debt obligations	196,844,339	-	-	196,844,339
TOTAL INVESTMENTS	6,663,114,164	-	-	6,663,114,164
<i>Derivatives *</i>				
Forward currency contracts	-	1,183,363	-	1,183,363
<b>Total financial assets at fair value through profit or loss</b>	<b>6,663,114,164</b>	<b>1,183,363</b>	<b>-</b>	<b>6,664,297,527</b>
<b>Liability Valuation Inputs</b>				
<i>Financial liabilities at fair value through profit or loss:</i>				
<i>Derivatives *</i>				
Forward currency contracts	-	(42,931)	-	(42,931)
<b>Total financial liabilities at fair value through profit or loss</b>	<b>-</b>	<b>(42,931)</b>	<b>-</b>	<b>(42,931)</b>

**30 September 2024**

**Quality**

	Level 1 US\$	Level 2 US\$	Level 3 US\$	Total US\$
<b>Asset Valuation Inputs</b>				
<i>Financial assets at fair value through profit or loss:</i>				
Equities	4,307,324,917	-	-	4,307,324,917
Debt obligations				
U.S. government	120,255,141	-	-	120,255,141
Total debt obligations	120,255,141	-	-	120,255,141
Short-term investments	6,633,588	-	-	6,633,588
TOTAL INVESTMENTS	4,434,213,646	-	-	4,434,213,646
<i>Derivatives *</i>				
Forward currency contracts	-	970,948	-	970,948
<b>Total financial assets at fair value through profit or loss</b>	<b>4,434,213,646</b>	<b>970,948</b>	<b>-</b>	<b>4,435,184,594</b>

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**8. Fair value information (continued)**

**Fair value hierarchy (continued)**

**30 September 2024 (continued)**

Quality had no financial liabilities as at 30 September 2024.

\* The tables above are based on market values or unrealised appreciation/(depreciation) rather than the notional amounts of derivatives.

**9. Investment and other risks**

The Company's investment activities expose it to the various types of risks which are associated with the financial instruments and markets in which the Company's Funds invest including but not limited to: market risk (i.e. price risk, interest rate risk, and currency), credit risk and illiquidity risk. The Funds are exposed to other risks and investors should refer to the prospectus for a more detailed discussion of the risks inherent in investing in the Funds.

The Company's risk management policies seek to minimise the potential adverse effects of these risks on each Fund's financial performance in order to satisfy the investment objectives of the Funds.

There can be no assurance that a Fund will achieve its investment objective. Prospective investors should read the entire prospectus and consult with their own advisers before subscribing for shares. Shares should only be purchased as a supplement to an overall investment programme and only by investors able to undertake the risks involved. The Investment Manager's assessment of the prospects of investments may not prove accurate. No assurance can be given that any investment or trading strategy implemented by the Investment Manager on behalf of the Fund will be successful and, because of the speculative nature of the Fund's investment and trading strategy, investors may suffer a significant loss of their invested capital, including loss of the entire investment. The value of shares may rise or fall, as the capital value of the securities in which each Fund invests may fluctuate. The investment income of each Fund is based on the income earned on the securities it holds, less expenses incurred. Therefore, each Fund's investment income may be expected to fluctuate in response to changes in such expenses or income.

The Board of Directors of the Company meet on a quarterly basis and, at these meetings, the Board of Directors reviews the investment performance and reports prepared by the Investment Manager. The Board of Directors delegates the day-to-day responsibility for investment management to the Investment Manager, who is responsible for ensuring that the Funds are managed within the terms of the investment guidelines and limits set out in the Company's prospectus (including any supplements there-to) and the Investment Manager's own internal investment guidelines and limits.

The Fund's investments comply with the investment restrictions contained in the Central Bank's UCITS Regulations and related guidance. Quality uses the "commitment approach" to calculate the global exposure of the Fund in accordance with the requirements of the Central Bank. See section entitled "Measurement of Market Risk and Leverage using the Commitment Approach".

Risk control is an integral part of the Investment Manager's investment construction process, rather than being carried out as a separate function. The integration of the investment control processes into the quantitative methods assists in preventing deviations from investment restrictions in the Fund. Thus, where possible, investment guidelines are programmed into optimisation routines, ensuring that guidelines with respect to maximum and minimum exposures are measured and adjusted as necessary. Investments of each Fund are reviewed by the relevant GMO LLC portfolio manager to ensure that the guidelines are understood and followed with respect to such areas as permitted investments, derivatives usage and out-of-benchmark exposures.

**(a) Market risk**

Market risk arises mainly from uncertainty about future values of financial instruments held, specifically from price, currency and interest rate movements. This is the general risk attendant to all investments that the value of a particular investment will change in a way detrimental to the Fund's interests. It represents the potential gains or losses a Fund might suffer through holding positions in the face of market movements.

The Investment Manager considers the asset allocation of the portfolio in order to minimise the risk associated with particular countries or industry sectors whilst continuing to follow the Fund's investment objectives.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**9. Investment and other risks (continued)**

**(a) Market risk (continued)**

*(i) Price risk*

Price risk is the risk that the fair value or future cash flows of a security or financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual security or financial instrument or its issuer, or factors affecting similar securities or financial instruments traded in the market. The Fund's price risk is primarily managed by holding a diversified basket of securities to reduce the risk that a price change of a particular investment will have a material impact on the Fund.

As outlined in the prospectus, the securities in which the Funds of the Company may invest shall include, without limitation, common stocks, depositary receipts, debt securities and related securities such as convertibles, preferred stocks, income trusts, royalty trusts, exchange-traded funds, REITs, private placements, rights, warrants and indexed securities.

Some risks of investing globally in equity securities may include changes in currency exchange rates, exchange control regulations, expropriation of assets or nationalisation, imposition of withholding taxes on dividend or interest payments, and difficulty in obtaining and enforcing judgements against entities. Also, to the extent a Fund takes short positions, increases in the market value of equity securities may be adverse to the Fund. Certain issuers of equity securities may be subject to different, often less comprehensive accounting, reporting and disclosure requirements, may be listed on less liquid and more volatile markets, and may be subject to high brokerage commissions and other fees. There are also special tax considerations which apply to securities of certain issuers. The value of certain assets as measured in U.S. Dollars may be affected by changes in currency rates and exchange control regulations. Some currency exchange costs may be incurred when the Fund changes investments from one country to another. Currency exchange rates may fluctuate significantly over short periods of time.

In addition, the Investment Manager may, where appropriate in the context of the Fund, invest in a wide variety of exchange-traded and OTC derivatives for investment purposes and/or efficient portfolio management purposes, as the case may be.

Details of open derivatives are included in the Statements of Investments of the Fund. All realised/unrealised gains/losses arising during the period are included in the Statement of Comprehensive Income.

Past performance is no indication of future results. There can be no assurance that the return of the Fund will meet or exceed its benchmark. The amount of the excess return variability (tracking error) is one measure of a Fund's risk versus its benchmark index.

The risk disclosure provided is based on historical data and is a relative estimate of risk. The analysis does not take account of the fact that future market price movements, correlations between markets and levels of market liquidity in conditions of market stress may bear no relation to historical patterns.

Beta is a commonly used estimate of the Fund's systematic risk. Very generally, beta is a measure of the co-movement of a portfolio in comparison to an index. The beta used in the table below has been estimated using rolling three year monthly observations and applied to the annualised monthly standard deviation of the benchmark returns over the same period to obtain the increase/decrease to the Fund's net assets. The Investment Manager believes this methodology provides a reasonable and objective estimate of the Fund's systematic risk.

<b>Fund</b>	<b>Index</b>	<b>30 September 2025 Beta</b>	<b>30 September 2024 Beta</b>
Quality Class A USD	MSCI World	0.93	0.91

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**9. Investment and other risks (continued)**

**(a) Market risk (continued)**

*(i) Price risk (continued)*

At 30 September 2025 and 30 September 2024, if the indices shown in the following tables had increased or decreased by the percentages shown with all other variables held constant, this would have increased or reduced net assets attributable to redeemable participating shareholders, respectively by approximately the amounts below:

**30 September 2025**

<b>Fund</b>	<b>Index</b>	<b>Increase/ Decrease</b>	<b>Impact to Net Asset Value</b>
Quality Class A USD	MSCI World	11.72%	387,840,933

**30 September 2024**

<b>Fund</b>	<b>Index</b>	<b>Increase/ Decrease</b>	<b>Impact to Net Asset Value</b>
Quality Class A USD	MSCI World	15.30%	433,704,735

*(ii) Interest rate risk*

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The majority of Quality's financial assets and liabilities as at 30 September 2025 and 30 September 2024 were non-interest bearing.

*(iii) Currency risk*

Currency risk is the risk that fluctuations in exchange rates will adversely affect the market value of a Fund's investments and includes the risk that the currencies in which a Fund's investments are traded, in which the Fund receives income, and/or in which the Fund has taken a position, will decline in value relative to the currency in which the Fund is denominated. Currency risk also includes the risk that the currency to which the Fund has obtained exposure through hedging declines in value relative to the currency being hedged, in which event, the Fund is likely to realise a loss on both the hedging instrument and the currency being hedged. Currency exchange rates can fluctuate significantly for many reasons.

The details of the foreign currency exposures are disclosed in the notes below.

The Company is exposed to currencies of each of the countries in which it invests including those disclosed in the Statements of Investments.

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**9. Investment and other risks (continued)**

**(a) Market risk (continued)**

*(iii) Currency risk (continued)*

The following tables set out the Quality's net exposure to foreign currency risk as at 30 September 2025 and 30 September 2024.

Quality	Currency exposure on financial assets and financial liabilities at fair value through profit or loss	Currency exposure on other assets/(liabilities)	Forward currency contracts	Net currency exposure
As at 30 September 2025	US\$	US\$	US\$	US\$
<b>Currency</b>				
Euro	617,025,920	(434,627)	80,340,851	696,932,144
British Pound Sterling	461,684,890	19,280	44,488,100	506,192,270
Taiwan Dollar	265,773,672	(9,065,004)	(1,696,599)	255,012,069
Swiss Franc	92,376,221	660	10,371,758	102,748,639
Norwegian Krone	-	-	89,955,140	89,955,140
Other	40,923,390	149,288	40,406,506	81,479,184
<b>Total</b>	<b>1,477,784,093</b>	<b>(9,330,403)</b>	<b>263,865,756</b>	<b>1,732,319,446</b>

Quality	Currency exposure on financial assets and financial liabilities at fair value through profit or loss	Currency exposure on other assets/(liabilities)	Forward currency contracts	Net currency exposure
As at 30 September 2024	US\$	US\$	US\$	US\$
<b>Currency</b>				
British Pound Sterling	316,250,220	254,683	175,626,252	492,131,155
Euro	415,182,951	70,322	34,360,819	449,614,092
Taiwan Dollar	131,446,778	(3,620,961)	-	127,825,817
Swiss Franc	115,991,390	61	-	115,991,451
Norwegian Krone	-	335	42,128,157	42,128,492
Other	-	6,856	8,295,656	8,302,512
<b>Total</b>	<b>978,871,339</b>	<b>(3,288,704)</b>	<b>260,410,884</b>	<b>1,235,993,519</b>

As at 30 September 2025, had the exchange rate between the U.S. Dollar and other currencies to which Quality is exposed been increased or decreased by 10% with all other variables held constant, the increase or decrease in net assets attributable to redeemable participating shareholders would have amounted to approximately US\$173,231,945 (30 September 2024: US\$123,599,352). This sensitivity analysis is based on the assumption that the movements of non-U.S. Dollar currencies against the U.S. Dollar may have an effect on the valuation of Quality's investments. Please see the Statement of Investments for additional detail. The Investment Manager believes that a variation of 10% of U.S. Dollar against the non-U.S. Dollar currency basket represents a reasonable estimate of how such currency exchange rates may have potentially varied.

**(b) Credit risk**

A Fund takes on exposure to credit risk, which is the risk that a counterparty will default by failing to meet its obligations in accordance with agreed terms. A Fund will be exposed to a credit risk on parties with whom it trades, and will also bear the risk of settlement default.



**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**9. Investment and other risks (continued)**

**(b) Credit risk (continued)**

When a Fund enters into a contract with a counterparty, such as a repurchase or reverse repurchase agreement or an OTC derivatives contract, or lends its portfolio securities or allows an OTC derivative counterparty to retain possession of collateral, it runs the risk that the counterparty will be unable or unwilling to make timely settlement payments or otherwise honour its obligations. Lack of a common clearing facility creates counterparty risk. If a counterparty fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, a Fund could miss investment opportunities or otherwise hold investments it would prefer to sell, resulting in losses for the Fund. If the counterparty defaults, a Fund will have contractual remedies, but there can be no assurance that the counterparty will be able to meet its contractual obligations or that the Fund will be able to enforce its rights. In addition, a Fund may suffer losses if a counterparty fails to comply with applicable laws, regulations or other requirements. Counterparty risk is pronounced during unusually adverse market conditions and is particularly acute in environments (like those of 2008) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions.

Participants in OTC derivatives markets typically are not subject to the same level of credit evaluation and regulatory oversight as are members of exchange-based markets, and, therefore, OTC derivatives generally expose a Fund to greater counterparty risk than exchange-traded derivatives. A Fund is subject to the risk that a counterparty will not settle a transaction in accordance with its terms because of a dispute over the terms of the contract (whether or not bona fide) or because of a credit or liquidity problem. A Fund also may be exposed to similar risks with respect to brokers in jurisdictions where there are delayed settlement periods.

The Fund also is subject to counterparty risk because it executes its securities transactions through brokers and dealers. If a broker or dealer fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, the Fund could miss investment opportunities or be unable to dispose of investments they would prefer to sell, resulting in losses for the Fund.

There is a risk the counterparty might default on any OTC contract. The tables below detail the gross exposure on OTC derivatives to each counterparty.

	<b>Quality As at 30 September 2025</b>
<b>Counterparty</b>	<b>Credit Rating Exposure US\$</b>
Citibank N.A.	A+ 454
Goldman Sachs International	A+ 5
Morgan Stanley & Co. International Plc	A+ 1,080,717
State Street Bank and Trust Company	AA- 102,187
	<u>1,183,363</u>

	<b>Quality As at 30 September 2024</b>
<b>Counterparty</b>	<b>Credit Rating Exposure US\$</b>
Citibank N.A.	A+ 16,786
Morgan Stanley & Co. International Plc	A+ 97,920
State Street Bank and Trust Company	AA- 856,242
	<u>970,948</u>



**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**9. Investment and other risks (continued)**

**(b) Credit risk (continued)**

The following tables represent the credit ratings of the Fund's fixed income securities (excluding its exposure to derivative contracts):

**Quality**

<b>Credit rating</b>	<b>As at 30 September 2025 %</b>	<b>As at 30 September 2024 %</b>
Investment grade	100.00	100.00
	<u>100.00</u>	<u>100.00</u>

The Fund may invest in short-term investments, including money market funds and overnight deposits, for which maturities are typically three days or less. These investments are not included in the table above as credit ratings are not available for these securities.

**(c) Illiquidity risk**

Illiquidity risk is the risk that low trading volume, lack of a market maker, large position size, or legal restrictions (including daily price fluctuation limits or "circuit breakers") limits, delays or prevents a Fund from selling particular securities or closing derivative positions at desirable prices. In addition to these risks, a Fund is exposed to illiquidity risk when it has an obligation to purchase particular securities (e.g., as a result of entering into reverse repurchase agreements, writing a put, or closing a short position). To the extent a Fund's investments include asset-backed securities, distressed, defaulted or other low quality debt securities, emerging country debt or equity securities, or securities of companies with smaller market capitalizations or smaller total float-adjusted market capitalizations, it is subject to increased illiquidity risk. These types of investments can be difficult to value, exposing a Fund to the risk that the price at which it sells them will be less than the price at which they were valued when held by the Fund. Illiquidity risk also tends to be greater in times of financial stress. For example, inflation-protected securities issued by the U.S. Treasury ("TIPS") have experienced periods of greatly reduced liquidity during disruptions in fixed income markets, such as the events surrounding the bankruptcy of Lehman Brothers in 2008. Less liquid securities are often more susceptible than other securities to price declines when market prices decline generally.

A Fund may buy securities or other investments that are less liquid than those in its benchmark. The more illiquid investments a Fund has, the greater the likelihood of its paying redemption proceeds in-kind. Historically, credit markets have experienced periods characterised by a significant lack of liquidity, and they may experience similar periods in the future. If a Fund is required to sell less liquid investments to satisfy collateral posting requirements or to meet redemptions, those sales could, put significant downward price pressure on the market price of the securities being sold.

For the avoidance of doubt, none of the assets of the Fund were subject to special liquidity arrangements during the financial years ended 30 September 2025 and 30 September 2024 and no new arrangements were adopted to manage the liquidity of the Fund.

The liquidity profile of Quality's financial liabilities and derivative contracts as at 30 September 2025 and 30 September 2024 is as follows:

<b>As at 30 September 2025</b>	<b>Up to 1 year US\$</b>	<b>1 to 5 years US\$</b>	<b>Over 5 years US\$</b>	<b>Total US\$</b>
Forward currency contracts – gross inflows	13,264,774	-	-	13,264,774
Forward currency contracts – gross outflows	(13,307,705)	-	-	(13,307,705)
Bank overdraft	(1,170,062)	-	-	(1,170,062)
Payables	(80,837,914)	-	-	(80,837,914)
Net assets attributable to holders of redeemable participating shares	(6,605,390,654)	-	-	(6,605,390,654)
<b>Total liabilities</b>	<u>(6,687,441,561)</u>	<u>-</u>	<u>-</u>	<u>(6,687,441,561)</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**9. Investment and other risks (continued)**

**(c) Illiquidity risk (continued)**

<b>As at 30 September 2024</b>	<b>Up to 1 year US\$</b>	<b>1 to 5 years US\$</b>	<b>Over 5 years US\$</b>	<b>Total US\$</b>
Payables	(31,799,054)	-	-	(31,799,054)
Net assets attributable to holders of redeemable participating shares	(4,455,553,398)	-	-	(4,455,553,398)
<b>Total liabilities</b>	<b>(4,487,352,452)</b>	<b>-</b>	<b>-</b>	<b>(4,487,352,452)</b>

Illiquidity risk also arises from the redemption requests of investors. In highly volatile market conditions, the Fund may not easily liquidate assets needed to satisfy repurchase requests. In such conditions, a number of liquidity management tools may be employed to protect the Fund and its investors, including restrictions on repurchases; in-specie redemptions; temporary suspension of valuation, issue and repurchase of shares; and recalibration of the dilution adjustment amounts for swing pricing. Investors should refer to the prospectus for a more detailed discussion of the liquidity management tools.

**(d) Measurement of market risk and leverage using the commitment approach**

The Fund will seek to limit the market risk and leverage created through the use of derivatives by using the commitment approach. The commitment approach calculates leverage by measuring the market value of the underlying exposures of derivatives relative to the Fund's NAV.

**(e) Risks of cash and other high quality investments**

The Fund may temporarily invest a portion of its assets in cash or cash equivalents pending other investments or to maintain liquid assets required in connection with its investments. These cash equivalents and other high quality debt securities may include money market instruments, such as government-issued securities, bankers' acceptances, commercial paper, and bank certificates of deposit. If a depositary holds cash on behalf of the Fund, the Fund may be an unsecured creditor in the event of the insolvency of the depositary. In addition, the Fund will be subject to credit risk with respect to such a depositary, which may be heightened to the extent the Fund takes a temporary defensive position.

**(f) Service provider risks**

The Fund's Depositary and sub-custodian(s), if any, will have custody of the Fund's securities, cash, distributions and rights accruing to the Fund's securities accounts. If the Depositary or a sub-custodian holds cash on behalf of the Fund, the Fund may be an unsecured creditor in the event of the insolvency of the relevant entity. The Fund will be subject to credit risk with respect to a Depositary and its sub-custodians. The Depositary credit rating for the financial year ended 30 September 2025 was AA- (30 September 2024: AA-).

**10. Related party transactions**

Under FRS 102 Section 33: "Related Party Transactions", related parties are described as related if any one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

Please refer to Note 3 for information regarding Directors', Manager's and Investment Manager's fees. Transactions with these related parties were entered into during the financial year under review by the Company in the ordinary course of business and on normal commercial terms.

GMO LLC is the parent entity of GMO UK Limited and GMO Netherlands B.V.

Mr. David Bohan, who is a Director of the Company, is an employee of the Investment Manager. Mr. Arron Day, who is a Director of the Company, is an employee of GMO UK Limited.

During the financial year ended 30 September 2025, shareholders of Quality made in-specie redemptions of redeemable participating shares of US\$98,991,268 (30 September 2024: US\$Nil).

These transactions were conducted at arm's length in accordance with the connected party transaction policy of the Company, and the valuation of the transaction was certified by the Depositary.

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**10. Related party transactions (continued)**

The Board of Directors is not aware of any transactions with related parties during the financial years ended 30 September 2025 or 30 September 2024, other than those included in these financial statements.

**11. Soft commission/direct brokerage**

The Investment Manager may use a portion of the commissions generated when executing transactions to acquire external research and brokerage services. Specifically, the Investment Manager may utilise commissions (typically only for transactions in listed equities) to purchase eligible brokerage and research services where those services assist in the investment decision-making process for the Fund and where the Investment Manager in good faith believes the amount of the commission is reasonable in relation to the value of the product or services provided by the broker/dealer.

**12. Concentration of principal shareholders**

The following table details the number of shareholders with significant holdings of at least 20% of a class of shares of the Fund and the percentage of that holding of the Fund's NAV as at 30 September 2025 and 30 September 2024.

Quality	Number of Shareholders As at	% of Shares As at	Number of Shareholder As at	% of Shares As at
Class of Shares	30 September 2025	30 September 2025	30 September 2024	30 September 2024
Class A AUD <sup>1</sup>	-	-	1	100.00
Class A EUR	1	65.37	2	53.24
Class A GBP	-	-	1	70.37
Class A SGD	2	74.33	3	96.07
Class A USD	1	28.55	1	47.34
Class C EUR Distributing	1	94.95	1	91.51
Class C GBP Distributing	2	100.00	1	100.00
Class C USD Distributing	2	71.69	2	73.12
Class D USD <sup>2</sup>	2	100.00	1	100.00
Class DH NOK	1	100.00	1	100.00
Class E EUR	2	82.19	2	90.42
Class E GBP <sup>3</sup>	1	100.00	-	-
Class E USD	1	90.36	2	83.75
Class E USD Distributing <sup>4</sup>	1	100.00	-	-
Class F EUR <sup>5</sup>	1	97.22	-	-
Class F EUR Distributing <sup>5</sup>	2	100.00	-	-
Class F GBP Distributing <sup>5</sup>	1	98.04	-	-
Class F USD <sup>5</sup>	2	81.78	-	-
Class F USD Distributing <sup>5</sup>	2	99.56	-	-
Class FH EUR <sup>5</sup>	2	98.03	-	-
Class FN EUR <sup>6</sup>	1	100.00	-	-
Class FN USD <sup>6</sup>	1	99.85	-	-
Class G EUR <sup>5</sup>	1	100.00	-	-
Class G USD <sup>5</sup>	2	100.00	-	-
Class GH AUD <sup>7</sup>	1	100.00	-	-
Class GH SGD <sup>5</sup>	1	98.68	-	-
Class H EUR <sup>8</sup>	1	67.16	1	84.98
Class H GBP <sup>9</sup>	2	91.93	1	82.48
Class H NOK <sup>10</sup>	1	100.00	-	-
Class J AUD	1	100.00	1	100.00
Class J EUR	1	100.00	1	100.00
Class J GBP <sup>11</sup>	1	100.00	1	100.00
Class J HKD <sup>12</sup>	1	100.00	-	-
Class J SGD	1	100.00	1	100.00

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**12. Concentration of principal shareholders (continued)**

Quality (continued)	Number of Shareholders As at	% of Shares As at	Number of Shareholder As at	% of Shares As at
Class of Shares	30 September 2025	30 September 2025	30 September 2024	30 September 2024
Class J USD	1	87.68	1	100.00
Class JH AUD <sup>13</sup>	1	100.00	-	-
Class JH CHF <sup>13</sup>	1	100.00	-	-
Class JH EUR <sup>13</sup>	1	100.00	-	-
Class JH SGD <sup>13</sup>	1	100.00	-	-
Class JU USD <sup>14</sup>	1	100.00	-	-
Class M GBP <sup>13</sup>	2	89.80	-	-
Class M GBP Distributing <sup>5</sup>	1	94.96	-	-
Class M USD Distributing <sup>13</sup>	1	89.53	-	-
Class O USD <sup>13</sup>	1	92.21	-	-
Class OH AUD <sup>13</sup>	1	100.00	-	-
Class OH CHF <sup>13</sup>	1	96.71	-	-
Class OH EUR <sup>13</sup>	1	96.12	-	-
Class OH GBP <sup>13</sup>	1	90.70	-	-
Class OH HKD <sup>13</sup>	1	100.00	-	-
Class OH SGD <sup>13</sup>	1	100.00	-	-
Class R SGD	1	93.60	1	97.76
Class R USD	1	91.32	1	92.94
Class Z SGD	1	100.00	1	100.00
Class ZH SGD	1	100.00	1	100.00

<sup>1</sup> Share class launched on 17 September 2024 and terminated on 16 July 2025.

<sup>2</sup> Share class launched on 29 February 2024.

<sup>3</sup> Share class launched on 19 August 2025.

<sup>4</sup> Share class launched on 5 September 2025.

<sup>5</sup> Share class launched on 21 November 2024.

<sup>6</sup> Share class launched on 7 March 2025.

<sup>7</sup> Share class launched on 22 November 2024.

<sup>8</sup> Share class launched on 1 November 2023.

<sup>9</sup> Share class launched on 8 November 2023.

<sup>10</sup> Share class launched on 1 November 2024.

<sup>11</sup> Share class launched on 11 October 2023.

<sup>12</sup> Share class launched on 21 February 2025.

<sup>13</sup> Share class launched on 17 December 2024.

<sup>14</sup> Share class launched on 11 February 2025.

**13. Redeemable participating shares and share capital**

**Authorised**

The Company has variable share capital. The authorised share capital of the Company is divided into 500,000,000,000 shares of no par value. The Directors have the power to allot shares up to the authorised share capital of the Company.

**Subscriber shares**

The initial issued share capital of the Company was 38,997 subscriber shares of no par value. 38,994 subscriber shares are held by GMO UK Limited, one is held by the Investment Manager and two are held by Directors. The non-participating subscriber shares are not included as part of the NAV of the Company and do not entitle the holders to participate in the dividends or net assets of the Company.

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Redeemable participating shares**

The issued redeemable participating share capital is at all times equal to the NAV of the Company. Redeemable participating shares are generally redeemable at the shareholder's option. Each of the redeemable participating shares entitles the holder to attend and vote at meetings of the Company and of the Fund represented by those redeemable participating shares.

**Share transactions**

Quality	For the financial year ended 30 September 2025 Shares	For the financial year ended 30 September 2024 Shares
<b>Class A AUD<sup>1</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	9,000	-
Number of shares issued	-	9,000
Number of shares redeemed	(9,000)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>-</u>	<u>9,000</u>
<b>Class A EUR</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	216,796	37,661
Number of shares issued	3,401,649	186,486
Number of shares redeemed	(1,877,684)	(7,351)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,740,761</u>	<u>216,796</u>
<b>Class A GBP</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	8,916,732	501,553
Number of shares issued	10,035,152	8,653,879
Number of shares redeemed	(9,157,431)	(238,700)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>9,794,453</u>	<u>8,916,732</u>
<b>Class A SGD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	383,969	226,261
Number of shares issued	269,075	203,244
Number of shares redeemed	(108,234)	(45,536)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>544,810</u>	<u>383,969</u>
<b>Class A USD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	22,874,781	12,123,287
Number of shares issued	10,556,143	14,515,346
Number of shares redeemed	(9,093,714)	(3,763,852)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>24,337,210</u>	<u>22,874,781</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class C EUR Distributing</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	276,832	20,498
Number of shares issued	109,507	256,334
Number of shares redeemed	(4,227)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<b>382,112</b>	<b>276,832</b>
<b>Class C GBP Distributing</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	23,059	23,259
Number of shares issued	7,960	-
Number of shares redeemed	(584)	(200)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<b>30,435</b>	<b>23,059</b>
<b>Class C USD Distributing</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	7,063,576	7,994,881
Number of shares issued	1,203,465	761,759
Number of shares redeemed	(1,290,154)	(1,693,064)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<b>6,976,887</b>	<b>7,063,576</b>
<b>Class D USD<sup>2</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	19,921,606	-
Number of shares issued	6,345,506	19,921,606
Number of shares redeemed	(606,905)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<b>25,660,207</b>	<b>19,921,606</b>
<b>Class DH NOK<sup>(H)</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	1,522,750	1,433,517
Number of shares issued	335,930	388,083
Number of shares redeemed	(416,337)	(298,850)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<b>1,442,343</b>	<b>1,522,750</b>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class E EUR</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	450,948	619,506
Number of shares issued	265,476	291,915
Number of shares redeemed	(495,930)	(460,473)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>220,494</u>	<u>450,948</u>
<b>Class E GBP<sup>3</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	1,808	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,808</u>	<u>-</u>
<b>Class E USD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	237,487	17,605
Number of shares issued	3,661,913	1,275,809
Number of shares redeemed	(67,520)	(1,055,927)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>3,831,880</u>	<u>237,487</u>
<b>Class E USD Distributing<sup>4</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	344,954	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>344,954</u>	<u>-</u>
<b>Class F EUR<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	1,814,545	-
Number of shares redeemed	(181,597)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,632,948</u>	<u>-</u>



**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class F EUR Distributing<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	224,540	-
Number of shares redeemed	(16,733)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>207,807</u>	<u>-</u>
<b>Class F GBP Distributing<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	1,380,175	-
Number of shares redeemed	(125,841)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,254,334</u>	<u>-</u>
<b>Class F USD<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	8,064,887	-
Number of shares redeemed	(832,357)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>7,232,530</u>	<u>-</u>
<b>Class F USD Distributing<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	2,491,163	-
Number of shares redeemed	(346,838)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>2,144,325</u>	<u>-</u>
<b>Class FH EUR<sup>(H), 5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	1,618,125	-
Number of shares redeemed	(77,196)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,540,929</u>	<u>-</u>



**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class FN EUR<sup>6</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	510	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>510</u>	<u>-</u>
<b>Class FN USD<sup>6</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	345,321	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>345,321</u>	<u>-</u>
<b>Class G EUR<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	500	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>500</u>	<u>-</u>
<b>Class G USD<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	5,088,182	-
Number of shares redeemed	(192,257)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>4,895,925</u>	<u>-</u>
<b>Class GH AUD<sup>(H), 7</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	375,738	-
Number of shares redeemed	(800)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>374,938</u>	<u>-</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class GH SGD<sup>(H)</sup>, 5</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	52,983	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>52,983</u>	<u>-</u>
<b>Class H EUR<sup>(H)</sup>, 8</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	1,210,436	-
Number of shares issued	172,216	1,664,279
Number of shares redeemed	(396,607)	(453,843)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>986,045</u>	<u>1,210,436</u>
<b>Class H GBP<sup>(H)</sup>, 9</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	4,982,574	-
Number of shares issued	2,210	6,766,541
Number of shares redeemed	(4,240,956)	(1,783,967)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>743,828</u>	<u>4,982,574</u>
<b>Class H NOK<sup>(H)</sup>, 10</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	1,972,101	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,972,101</u>	<u>-</u>
<b>Class J AUD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	62,244	7,178
Number of shares issued	95,158	55,066
Number of shares redeemed	(21,586)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>135,816</u>	<u>62,244</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class J EUR</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	107,937	9,893
Number of shares issued	40,519	98,044
Number of shares redeemed	(9,893)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>138,563</u>	<u>107,937</u>
<b>Class J GBP<sup>11</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	5,014	-
Number of shares issued	49,596	7,914
Number of shares redeemed	(6,000)	(2,900)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>48,610</u>	<u>5,014</u>
<b>Class J HKD<sup>12</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	64,496	-
Number of shares redeemed	(38,038)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>26,458</u>	<u>-</u>
<b>Class J SGD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	538,758	139,251
Number of shares issued	459,974	505,135
Number of shares redeemed	(123,784)	(105,628)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>874,948</u>	<u>538,758</u>
<b>Class J USD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	4,432,256	854,897
Number of shares issued	5,066,464	3,781,904
Number of shares redeemed	(1,541,954)	(204,545)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>7,956,766</u>	<u>4,432,256</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class JH AUD<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	268,244	-
Number of shares redeemed	(12,983)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>255,261</u>	<u>-</u>
<b>Class JH CHF<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	21,453	-
Number of shares redeemed	(706)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>20,747</u>	<u>-</u>
<b>Class JH EUR<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	80,117	-
Number of shares redeemed	(5,500)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>74,617</u>	<u>-</u>
<b>Class JH SGD<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	1,070,608	-
Number of shares redeemed	(49,732)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,020,876</u>	<u>-</u>
<b>Class JU USD<sup>14</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	2,045,115	-
Number of shares redeemed	(95,724)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>1,949,391</u>	<u>-</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class M GBP<sup>13</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	2,721,204	-
Number of shares redeemed	(153,733)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>2,567,471</u>	<u>-</u>
<b>Class M GBP Distributing<sup>5</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	14,589,132	-
Number of shares redeemed	(1,063,778)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>13,525,354</u>	<u>-</u>
<b>Class M USD Distributing<sup>13</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	99,287	-
Number of shares redeemed	-	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>99,287</u>	<u>-</u>
<b>Class O USD<sup>13</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	7,431,044	-
Number of shares redeemed	(911,293)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>6,519,751</u>	<u>-</u>
<b>Class OH AUD<sup>(H), 13</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	249,864	-
Number of shares redeemed	(4,909)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>244,955</u>	<u>-</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class OH CHF<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	427,811	-
Number of shares redeemed	(15,567)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>412,244</u>	<u>-</u>
<b>Class OH EUR<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	517,121	-
Number of shares redeemed	(16,750)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>500,371</u>	<u>-</u>
<b>Class OH GBP<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	646,825	-
Number of shares redeemed	(500)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>646,325</u>	<u>-</u>
<b>Class OH HKD<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	5,312	-
Number of shares redeemed	(390)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>4,922</u>	<u>-</u>
<b>Class OH SGD<sup>(H)</sup>, 13</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	-	-
Number of shares issued	657,813	-
Number of shares redeemed	(68,769)	-
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>589,044</u>	<u>-</u>

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

<b>Quality (continued)</b>	<b>For the financial year ended 30 September 2025 Shares</b>	<b>For the financial year ended 30 September 2024 Shares</b>
<b>Class R SGD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	7,598	606
Number of shares issued	13,578	20,295
Number of shares redeemed	(7,643)	(13,303)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>13,533</u>	<u>7,598</u>
<b>Class R USD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	597,820	290,341
Number of shares issued	266,760	346,104
Number of shares redeemed	(101,999)	(38,625)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>762,581</u>	<u>597,820</u>
<b>Class Z SGD</b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	68,329	77,086
Number of shares issued	2,420	-
Number of shares redeemed	(9,075)	(8,757)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>61,674</u>	<u>68,329</u>
<b>Class ZH SGD<sup>(H)</sup></b>		
<b>Movement in redeemable participating shares during the financial year</b>		
Shares in issue at the beginning of the financial year	339,566	398,695
Number of shares issued	3,336	39,134
Number of shares redeemed	(315,358)	(98,263)
<b>Redeemable participating shares in issue at the end of the financial year</b>	<u>27,544</u>	<u>339,566</u>

(H) Hedged share class.

- 1 Share class launched on 17 September 2024 and terminated on 16 July 2025.
- 2 Share class launched on 29 February 2024.
- 3 Share class launched on 19 August 2025.
- 4 Share class launched on 5 September 2025.
- 5 Share class launched on 21 November 2024.
- 6 Share class launched on 7 March 2025.
- 7 Share class launched on 22 November 2024.
- 8 Share class launched on 1 November 2023.
- 9 Share class launched on 8 November 2023.
- 10 Share class launched on 1 November 2024.
- 11 Share class launched on 11 October 2023.

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**13. Redeemable participating shares and share capital (continued)**

**Share transactions (continued)**

- 12 Share class launched on 21 February 2025.  
13 Share class launched on 17 December 2024.  
14 Share class launched on 11 February 2025.

**14. NAV comparison table**

Quality	As at 30 September 2025	As at 30 September 2024	As at 30 September 2023
<b>Class A AUD<sup>1</sup></b>			
Net assets	-	US\$123,610	-
Shares in issue	-	9,000	-
NAV per share	-	US\$13.73	-
	-	AUD19.80	-
<b>Class A EUR</b>			
Net assets	US\$55,302,619	US\$6,279,866	US\$807,125
Shares in issue	1,740,761	216,796	37,661
NAV per share	US\$31.77	US\$28.97	US\$21.43
	EUR27.04	EUR25.95	EUR20.24
<b>Class A GBP</b>			
Net assets	US\$587,660,367	US\$487,834,496	US\$20,304,527
Shares in issue	9,794,453	8,916,732	501,553
NAV per share	US\$60.00	US\$54.71	US\$40.48
	GBP44.57	GBP40.79	GBP33.17
<b>Class A SGD</b>			
Net assets	US\$11,974,938	US\$7,695,649	US\$3,355,456
Shares in issue	544,810	383,969	226,261
NAV per share	US\$21.98	US\$20.04	US\$14.83
	SGD28.34	SGD25.69	SGD20.24
<b>Class A USD</b>			
Net assets	US\$3,309,890,041	US\$2,836,741,022	US\$1,112,418,869
Shares in issue	24,337,210	22,874,781	12,123,287
NAV per share	US\$136.00	US\$124.01	US\$91.76
<b>Class C EUR Distributing</b>			
Net assets	US\$11,809,219	US\$7,854,514	US\$432,432
Shares in issue	382,112	276,832	20,498
NAV per share	US\$30.91	US\$28.37	US\$21.10
	EUR26.30	EUR25.42	EUR19.93
<b>Class C GBP Distributing</b>			
Net assets	US\$1,178,393	US\$819,656	US\$616,185
Shares in issue	30,435	23,059	23,259
NAV per share	US\$38.72	US\$35.55	US\$26.49
	GBP28.76	GBP26.50	GBP21.71
<b>Class C USD Distributing</b>			
Net assets	US\$216,662,167	US\$201,377,081	US\$169,882,465
Shares in issue	6,976,887	7,063,576	7,994,881
NAV per share	US\$31.05	US\$28.51	US\$21.25



**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**14. NAV comparison table (continued)**

Quality (continued)	As at 30 September 2025	As at 30 September 2024	As at 30 September 2023
<b>Class D USD<sup>2</sup></b>			
Net assets	US\$632,775,389	US\$447,555,479	-
Shares in issue	25,660,207	19,921,606	-
NAV per share	US\$24.66	US\$22.47	-
<b>Class DH NOK</b>			
Net assets	US\$46,745,181	US\$42,949,438	US\$29,956,084
Shares in issue	1,442,343	1,522,750	1,433,517
NAV per share	US\$32.41	US\$28.21	US\$20.90
	NOK323.37	NOK297.08	NOK222.36
<b>Class E EUR</b>			
Net assets	US\$7,713,961	US\$14,386,690	US\$14,627,605
Shares in issue	220,494	450,948	619,506
NAV per share	US\$34.98	US\$31.90	US\$23.61
	EUR29.77	EUR28.59	EUR22.30
<b>Class E GBP<sup>3</sup></b>			
Net assets	US\$50,541	-	-
Shares in issue	1,808	-	-
NAV per share	US\$27.96	-	-
	GBP20.77	-	-
<b>Class E USD</b>			
Net assets	US\$121,113,793	US\$6,844,898	US\$375,496
Shares in issue	3,831,880	237,487	17,605
NAV per share	US\$31.61	US\$28.82	US\$21.33
<b>Class E USD Distributing<sup>4</sup></b>			
Net assets	US\$7,078,371	-	-
Shares in issue	344,954	-	-
NAV per share	US\$20.52	-	-
<b>Class F EUR<sup>5</sup></b>			
Net assets	US\$38,165,313	-	-
Shares in issue	1,632,948	-	-
NAV per share	US\$23.37	-	-
	EUR19.89	-	-
<b>Class F EUR Distributing<sup>5</sup></b>			
Net assets	US\$4,844,142	-	-
Shares in issue	207,807	-	-
NAV per share	US\$23.31	-	-
	EUR19.84	-	-
<b>Class F GBP Distributing<sup>5</sup></b>			
Net assets	US\$35,089,024	-	-
Shares in issue	1,254,334	-	-
NAV per share	US\$27.97	-	-
	GBP20.78	-	-
<b>Class F USD<sup>5</sup></b>			
Net assets	US\$160,801,523	-	-
Shares in issue	7,232,530	-	-
NAV per share	US\$22.23	-	-

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**14. NAV comparison table (continued)**

Quality (continued)	As at 30 September 2025	As at 30 September 2024	As at 30 September 2023
<b>Class F USD Distributing<sup>5</sup></b>			
Net assets	US\$47,536,435	-	-
Shares in issue	2,144,325	-	-
NAV per share	US\$22.17	-	-
<b>Class FH EUR<sup>5</sup></b>			
Net assets	US\$39,476,806	-	-
Shares in issue	1,540,929	-	-
NAV per share	US\$25.62	-	-
	EUR21.80	-	-
<b>Class FN EUR<sup>6</sup></b>			
Net assets	US\$12,050	-	-
Shares in issue	510	-	-
NAV per share	US\$23.64	-	-
	EUR20.12	-	-
<b>Class FN USD<sup>6</sup></b>			
Net assets	US\$7,506,958	-	-
Shares in issue	345,321	-	-
NAV per share	US\$21.74	-	-
<b>Class G EUR<sup>5</sup></b>			
Net assets	US\$11,648	-	-
Shares in issue	500	-	-
NAV per share	US\$23.30	-	-
	EUR19.83	-	-
<b>Class G USD<sup>5</sup></b>			
Net assets	US\$108,464,704	-	-
Shares in issue	4,895,925	-	-
NAV per share	US\$22.15	-	-
<b>Class GH AUD<sup>(H), 7</sup></b>			
Net assets	US\$5,427,096	-	-
Shares in issue	374,938	-	-
NAV per share	US\$14.47	-	-
	AUD21.84	-	-
<b>Class GH SGD<sup>(H), 5</sup></b>			
Net assets	US\$891,708	-	-
Shares in issue	52,983	-	-
NAV per share	US\$16.83	-	-
	SGD21.70	-	-
<b>Class H EUR<sup>(H), 8</sup></b>			
Net assets	US\$31,840,728	US\$34,589,032	-
Shares in issue	986,045	1,210,436	-
NAV per share	US\$32.29	US\$28.58	-
	EUR27.48	EUR25.60	-
<b>Class H GBP<sup>(H), 9</sup></b>			
Net assets	US\$29,196,758	US\$178,943,010	-
Shares in issue	743,828	4,982,574	-
NAV per share	US\$39.25	US\$35.91	-
	GBP29.16	GBP26.77	-

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**14. NAV comparison table (continued)**

Quality (continued)	As at 30 September 2025	As at 30 September 2024	As at 30 September 2023
<b>Class H NOK<sup>(H), 10</sup></b>			
Net assets	US\$44,055,937	-	-
Shares in issue	1,972,101	-	-
NAV per share	US\$22.34	-	-
	NOK222.90	-	-
<b>Class J AUD</b>			
Net assets	US\$2,731,951	US\$1,147,543	US\$98,423
Shares in issue	135,816	62,244	7,178
NAV per share	US\$20.12	US\$18.44	US\$13.71
	AUD30.35	AUD26.57	AUD21.24
<b>Class J EUR</b>			
Net assets	US\$4,305,347	US\$3,074,045	US\$209,571
Shares in issue	138,563	107,937	9,893
NAV per share	US\$31.07	US\$28.48	US\$21.18
	EUR26.44	EUR25.52	EUR20.01
<b>Class J GBP<sup>11</sup></b>			
Net assets	US\$1,713,738	US\$162,021	-
Shares in issue	48,610	5,014	-
NAV per share	US\$35.25	US\$32.31	-
	GBP26.19	GBP24.09	-
<b>Class J HKD<sup>12</sup></b>			
Net assets	US\$725,418	-	-
Shares in issue	26,458	-	-
NAV per share	US\$27.42	-	-
	HKD213.32	-	-
<b>Class J SGD</b>			
Net assets	US\$20,894,614	US\$11,792,759	US\$2,266,830
Shares in issue	874,948	538,758	139,251
NAV per share	US\$23.88	US\$21.89	US\$16.28
	SGD30.79	SGD28.06	SGD22.22
<b>Class J USD</b>			
Net assets	US\$268,630,633	US\$137,158,554	US\$19,676,877
Shares in issue	7,956,766	4,432,256	854,897
NAV per share	US\$33.76	US\$30.95	US\$23.02
<b>Class JH AUD<sup>(H), 13</sup></b>			
Net assets	US\$3,653,122	-	-
Shares in issue	255,261	-	-
NAV per share	US\$14.31	-	-
	AUD21.59	-	-
<b>Class JH CHF<sup>(H), 13</sup></b>			
Net assets	US\$547,527	-	-
Shares in issue	20,747	-	-
NAV per share	US\$26.39	-	-
	CHF21.00	-	-
<b>Class JH EUR<sup>(H), 13</sup></b>			
Net assets	US\$1,879,030	-	-
Shares in issue	74,617	-	-
NAV per share	US\$25.18	-	-
	EUR21.43	-	-

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**14. NAV comparison table (continued)**

Quality (continued)	As at 30 September 2025	As at 30 September 2024	As at 30 September 2023
<b>Class JH SGD<sup>(H), 13</sup></b>			
Net assets	US\$16,942,147	-	-
Shares in issue	1,020,876	-	-
NAV per share	US\$16.60	-	-
	SGD21.40	-	-
<b>Class JU USD<sup>14</sup></b>			
Net assets	US\$41,422,837	-	-
Shares in issue	1,949,391	-	-
NAV per share	US\$21.25	-	-
<b>Class M GBP<sup>13</sup></b>			
Net assets	US\$71,464,778	-	-
Shares in issue	2,567,471	-	-
NAV per share	US\$27.83	-	-
	GBP20.68	-	-
<b>Class M GBP Distributing<sup>5</sup></b>			
Net assets	US\$378,479,857	-	-
Shares in issue	13,525,354	-	-
NAV per share	US\$27.98	-	-
	GBP20.79	-	-
<b>Class M USD Distributing<sup>13</sup></b>			
Net assets	US\$2,170,220	-	-
Shares in issue	99,287	-	-
NAV per share	US\$21.86	-	-
<b>Class O USD<sup>13</sup></b>			
Net assets	US\$142,794,999	-	-
Shares in issue	6,519,751	-	-
NAV per share	US\$21.90	-	-
<b>Class OH AUD<sup>(H), 13</sup></b>			
Net assets	US\$3,517,201	-	-
Shares in issue	244,955	-	-
NAV per share	US\$14.36	-	-
	AUD21.67	-	-
<b>Class OH CHF<sup>(H), 13</sup></b>			
Net assets	US\$10,916,663	-	-
Shares in issue	412,244	-	-
NAV per share	US\$26.48	-	-
	CHF21.07	-	-
<b>Class OH EUR<sup>(H), 13</sup></b>			
Net assets	US\$12,642,686	-	-
Shares in issue	500,371	-	-
NAV per share	US\$25.27	-	-
	EUR21.50	-	-
<b>Class OH GBP<sup>(H), 13</sup></b>			
Net assets	US\$18,946,441	-	-
Shares in issue	646,325	-	-
NAV per share	US\$29.31	-	-
	GBP21.77	-	-

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**14. NAV comparison table (continued)**

Quality (continued)	As at 30 September 2025	As at 30 September 2024	As at 30 September 2023
<b>Class OH HKD<sup>(H)</sup>, 13</b>			
Net assets	US\$136,733	-	-
Shares in issue	4,922	-	-
NAV per share	US\$27.78	-	-
	HKD216.12	-	-
<b>Class OH SGD<sup>(H)</sup>, 13</b>			
Net assets	US\$9,809,946	-	-
Shares in issue	589,044	-	-
NAV per share	US\$16.65	-	-
	SGD21.47	-	-
<b>Class R SGD</b>			
Net assets	US\$323,379	US\$166,589	US\$9,912
Shares in issue	13,533	7,598	606
NAV per share	US\$23.90	US\$21.93	US\$16.36
	SGD30.81	SGD28.11	SGD22.32
<b>Class R USD</b>			
Net assets	US\$25,061,521	US\$18,026,160	US\$6,518,042
Shares in issue	762,581	597,820	290,341
NAV per share	US\$32.86	US\$30.15	US\$22.45
<b>Class Z SGD</b>			
Net assets	US\$1,680,023	US\$1,689,105	US\$1,403,235
Shares in issue	61,674	68,329	77,086
NAV per share	US\$27.24	US\$24.72	US\$18.20
	SGD35.12	SGD31.69	SGD24.85
<b>Class ZH SGD<sup>(H)</sup></b>			
Net assets	US\$724,033	US\$8,342,181	US\$6,901,602
Shares in issue	27,544	339,566	398,695
NAV per share	US\$26.29	US\$24.57	US\$17.31
	SGD33.89	SGD31.50	SGD23.63

(H) Hedged share class.

- 1 Share class launched on 17 September 2024 and terminated on 16 July 2025.
- 2 Share class launched on 29 February 2024.
- 3 Share class launched on 19 August 2025.
- 4 Share class launched on 5 September 2025.
- 5 Share class launched on 21 November 2024.
- 6 Share class launched on 7 March 2025.
- 7 Share class launched on 22 November 2024.
- 8 Share class launched on 1 November 2023.
- 9 Share class launched on 8 November 2023.
- 10 Share class launched on 1 November 2024.
- 11 Share class launched on 11 October 2023.
- 12 Share class launched on 21 February 2025.
- 13 Share class launched on 17 December 2024.
- 14 Share class launched on 11 February 2025.

**15. Contingent liabilities**

The Investment Manager is not aware of any contingent liabilities as at 30 September 2025 or as at 30 September 2024.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**16. Additional information for the distribution in Switzerland**

**Representative in Switzerland**

State Street Bank International GmbH, Munich, Zurich Branch, Kalanderplatz 5, CH - 8027 Zurich is the representative in Switzerland.

**Paying Agent in Switzerland**

State Street Bank International GmbH, Munich, Zurich Branch, Kalanderplatz 5, CH - 8027 Zurich is the paying agent in Switzerland.

**Place where the relevant documents may be obtained:**

The prospectus, the Key Investor Information Document (KIID), the most recent annual and semi-annual reports as well as the portfolio changes may be obtained free of charge from the representative and paying agent in Switzerland.

**Total expense ratio**

The total expense ratios for the financial year ended 30 September 2025 for classes distributed in Switzerland and active as of 30 September 2025 are set forth in the table below.

<b>Quality</b>	<b>Total Expense Ratio (%)</b>
Class F EUR <sup>1</sup>	0.44%
Class F EUR Distributing <sup>1</sup>	0.44%
Class F USD <sup>1</sup>	0.44%
Class F USD Distributing <sup>1</sup>	0.44%
Class FH EUR <sup>1</sup>	0.44%
Class FN EUR <sup>2</sup>	0.44%
Class FN USD <sup>2</sup>	0.44%
Class J USD	1.05%
Class JH AUD <sup>3</sup>	0.83%
Class JH CHF <sup>3</sup>	0.83%
Class JH EUR <sup>3</sup>	0.83%
Class JH SGD <sup>3</sup>	0.83%
Class JU USD <sup>4</sup>	0.83%
Class O USD <sup>3</sup>	0.44%
Class OH AUD <sup>3</sup>	0.44%
Class OH CHF <sup>3</sup>	0.44%
Class OH EUR <sup>3</sup>	0.44%
Class OH GBP <sup>3</sup>	0.44%
Class OH HKD <sup>3</sup>	0.44%
Class OH SGD <sup>3</sup>	0.44%

<sup>1</sup>Share class launched on 21 November 2024.

<sup>2</sup>Share class launched on 7 March 2025.

<sup>3</sup>Share class launched on 17 December 2024.

<sup>4</sup>Share class launched on 11 February 2025.

The total expense ratio is annualised for periods less than one year.

The total expense ratio calculation includes all operating expenses for the financial year ended 30 September 2025 and excludes interest paid, foreign exchange, transaction and dealing costs, and foreign withholding taxes, if any. For classes launched after 1 October 2024, the total expense ratio is an estimate based on actual costs over the financial year.

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

**16. Additional information for the distribution in Switzerland (continued)**

**Performance**

The below performance overview includes classes distributed in Switzerland and active as of 30 September 2025 and are presented net of expenses.

Share Class	Currency	Net return % 30 September 2025	Net return % 30 September 2024	Net return % 30 September 2023
Class F EUR <sup>1</sup>	EUR	(0.55)	-	-
Class F EUR Distributing <sup>1</sup>	EUR	(0.54)	-	-
Class F USD <sup>1</sup>	USD	11.15	-	-
Class F USD Distributing <sup>1</sup>	USD	11.17	-	-
Class FH EUR <sup>1</sup>	EUR	9.00	-	-
Class FN EUR <sup>2</sup>	EUR	0.60	-	-
Class FN USD <sup>2</sup>	USD	8.70	-	-
Class J USD	USD	9.08	34.45	26.00
Class JH AUD <sup>3</sup>	AUD	7.95	-	-
Class JH CHF <sup>3</sup>	CHF	5.00	-	-
Class JH EUR <sup>3</sup>	EUR	7.15	-	-
Class JH SGD <sup>3</sup>	SGD	7.00	-	-
Class JU USD <sup>4</sup>	USD	6.25	-	-
Class O USD <sup>3</sup>	USD	9.50	-	-
Class OH AUD <sup>3</sup>	AUD	8.35	-	-
Class OH CHF <sup>3</sup>	CHF	5.35	-	-
Class OH EUR <sup>3</sup>	EUR	7.50	-	-
Class OH GBP <sup>3</sup>	GBP	8.85	-	-
Class OH HKD <sup>3</sup>	HKD	8.06	-	-
Class OH SGD <sup>3</sup>	SGD	7.35	-	-

<sup>1</sup> Share class launched on 21 November 2024.

<sup>2</sup> Share class launched on 7 March 2025.

<sup>3</sup> Share class launched on 17 December 2024.

<sup>4</sup> Share class launched on 11 February 2025.

**17. Significant events during the financial year**

On 8 October 2024, the Company issued a second supplemental prospectus to create seven new share classes in Quality, namely Class G USD, Class G EUR, Class GH SGD, Class GH AUD, Class M USD Distributing, Class M GBP Distributing and Class N USD.

On 7 November 2024, the Company issued a third supplemental prospectus to create ten new share classes in Quality, namely Class JH EUR, Class JH CHF, Class M GBP, Class O USD, Class OH EUR, Class OH GBP, Class OH SGD, Class OH AUD, Class OH HKD and Class OH CHF.

On 10 February 2025, the Company issued a fourth supplemental prospectus to create one new share class in Quality, namely Class JU USD.

On 24 February 2025, the Company issued a fifth supplemental prospectus to create two new share classes in Quality, namely Class FN USD and Class FN EUR.

On 7 April 2025, the Company issued a sixth supplemental prospectus to create five new share classes in Quality, namely Class GBP Distributing, Class USD Distributing, Class JH GBP, Class JH CNH and Class OH CNH.

On 11 June 2025, the Company issued a seventh supplemental prospectus to modify the manner in which the Class DH NOK Share Class of Quality is hedged.

---

**GMO FUNDS PLC**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025**

---

**17. Significant events during the financial year (continued)**

On 18 July 2025, the Company issued an eighth supplemental prospectus to create one new share class in Quality, namely, Class E USD Distributing.

There were no other significant events during the financial year end requiring financial statement disclosure.

**18. Significant events since the financial year end**

On 8 December 2025, the Company issued a ninth supplemental prospectus to create one new share class in Quality, namely, Class P NOK.

There were no other significant events occurring since the financial year end requiring financial statement disclosure.



**GMO FUNDS PLC**  
**GMO QUALITY INVESTMENT FUND**  
**STATEMENT OF CHANGES IN THE PORTFOLIO (UNAUDITED)**

The following statement of changes in the portfolio reflect the aggregate purchases of a security exceeding 1% of the total value of purchases and aggregate disposals greater than 1% of the total sales in the financial year. At a minimum, the largest 20 purchases and 20 sales are required to be disclosed, if applicable.

***Schedule of material purchases for the financial year ended 30 September 2025***

<b>Security Description</b>	<b>Nominal</b>	<b>Cost US\$</b>
State Street Global Advisors Liquidity PLC - US Treasury Liquidity Fund	1,372,054,340	1,372,054,340
U.S. Treasury Floating Rate Note, 4.05%, due 30/04/27	554,000,000	554,250,170
U.S. Treasury Floating Rate Note, 4.09%, due 31/10/26	396,500,000	396,959,748
U.S. Treasury Floating Rate Note, 4.05%, due 31/07/27	362,000,000	361,815,420
U.S. Treasury Floating Rate Note, 3.99%, due 31/01/27	312,000,000	312,076,800
Thermo Fisher Scientific, Inc.	348,652	171,019,946
Microsoft Corp.	334,040	143,659,800
UnitedHealth Group, Inc.	287,014	110,631,209
Broadcom, Inc.	606,658	107,988,953
Salesforce, Inc.	379,439	101,342,357
Constellation Brands, Inc.	452,162	89,045,309
Elevance Health, Inc.	249,901	88,265,964
Alphabet, Inc. Class A	485,388	87,379,203
Accenture PLC	296,279	86,527,919
Abbott Laboratories	610,280	76,255,419
Apple, Inc.	327,872	75,331,129
Uber Technologies, Inc.	1,063,686	73,935,546
Haleon PLC	14,853,041	72,318,769
Taiwan Semiconductor Manufacturing Co Ltd.	2,178,709	72,290,725
Meta Platforms, Inc.	113,237	71,135,224
Johnson & Johnson	403,867	64,838,437
US Bancorp.	1,402,307	64,478,827
Novo Nordisk A/S Class B	778,942	62,076,125
Dassault Systemes SE	1,593,914	59,816,917
U.S. Treasury Floating Rate Note, 4.73%, due 31/07/26	58,000,000	57,965,758

***Schedule of material sales for the financial year ended 30 September 2025***

<b>Security Description</b>	<b>Nominal</b>	<b>Proceeds US\$</b>
State Street Global Advisors Liquidity PLC - US Treasury Liquidity Fund	1,378,687,928	1,378,687,928
U.S. Treasury Floating Rate Note, 4.05%, due 30/04/27	554,000,000	554,124,250
U.S. Treasury Floating Rate Note, 4.09%, due 31/10/26	396,500,000	397,187,606
U.S. Treasury Floating Rate Note, 3.99%, due 31/01/27	312,000,000	311,958,020
U.S. Treasury Floating Rate Note, 4.73%, due 31/07/26	178,400,000	178,369,687
U.S. Treasury Floating Rate Note, 4.05%, due 31/07/27	165,000,000	164,903,400
Oracle Corp.	385,768	93,880,393
Otis Worldwide Corp.	910,905	87,157,047
Safran SA	265,025	77,187,984
Wells Fargo & Co	804,543	62,888,518
Roche Holding AG	168,097	48,913,406
Coca-Cola Co.	676,238	47,630,056
Alphabet, Inc. Class A	249,779	47,349,065
Visa, Inc.	136,514	46,145,924
Intuitive Surgical, Inc.	67,184	35,710,798
TJX Cos., Inc.	294,582	33,832,951
SAP SE	116,724	31,574,723
Apple, Inc.	159,614	31,040,612
KLA Corp.	32,914	29,138,847
Broadcom, Inc.	110,933	26,762,594

---

## GMO FUNDS PLC DIRECTORY

---

**Board of Directors (non-executive)**

Mr. David Bohan (United States)  
Ms. Eimear Cowhey (Ireland)<sup>1</sup>  
Mr. Arron Day (United Kingdom)  
Mr. John Fitzpatrick (Ireland)<sup>1</sup>

**Depository**

State Street Custodial Services (Ireland) Limited  
78 Sir John Rogerson's Quay  
Dublin 2  
Ireland

**Administrator**

State Street Fund Services (Ireland) Limited  
78 Sir John Rogerson's Quay  
Dublin 2  
Ireland

**Company Secretary**

Bradwell Limited  
10 Earlsfort Terrace  
Dublin 2  
Ireland

**Auditor**

PricewaterhouseCoopers  
Chartered Accountants and Statutory Audit Firm  
One Spencer Dock  
North Wall Quay  
Dublin 1  
Ireland

**Investment Manager**

Grantham, Mayo, Van Otterloo & Co. LLC  
53 State Street, 33<sup>rd</sup> Floor  
Boston  
Massachusetts 02109  
USA

**Legal Adviser**

Arthur Cox LLP  
10 Earlsfort Terrace  
Dublin 2  
Ireland

**Distributor and UK Facilities Agent**

GMO UK Limited  
No. 1 London Bridge  
London SE1 9BG  
England

**Registered Office**

78 Sir John Rogerson's Quay  
Dublin 2  
Ireland

**Distributor**

GMO Netherlands B.V.  
Gustav Mahlerplein 109-115  
26th floor  
1082 MS Amsterdam  
The Netherlands

**Manager**

Waystone Management Company (IE) Limited  
35 Shelbourne Road, 4th Floor  
Ballsbridge  
Dublin  
D04 A4E  
Ireland

**Representative in Switzerland**

State Street Bank International GmbH, Munich, Zurich Branch  
Kalanderplatz 5  
Postfach  
8027 Zürich  
Switzerland

**Paying Agent in Switzerland**

State Street Bank International GmbH, Munich, Zurich Branch  
Kalanderplatz 5  
Postfach  
8027 Zürich  
Switzerland

**Registered Number:** 351477

<sup>1</sup> Independent Director.